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Abstract	
	
This	MPH	dissertation	 is	a	systematic	 review	of	 the	 factors	contributing	to	vaccine	hesitancy	 in	Africa.	
The	dissertation	comprises	of	the	following	three	parts:	
	
The	 research	 protocol	 (Part	 A)	 outlines	 the	 background	 and	 proposed	methods	 of	 the	 research.	 The	
protocol	 outlines	 the	 search	 strategy	 used	 to	 identify	 research	 eligible	 for	 this	 review	 according	 to	
defined	 criteria.	 The	 objective	 of	 this	 research	 was	 to	 identify	 determinants	 of	 vaccine	 hesitancy	 in	
Africa.	The	protocol	describes	data	collection	methods	and	the	analysis	plan	of	this	research	in	order	to	
address	the	objective.	
	
The	 literature	 review	 (Part	 B)	 provides	 a	 summary	 and	 interpretation	 of	 the	 current	 literature	 on	
barriers	 to	 vaccination,	 specifically	 vaccine	 hesitancy	 and	 its	 impacts	 on	 immunisation	 programs.	 The	
literature	 review	 identifies	 discord	 among	 literature	 in	 defining	 vaccine	 hesitancy	 and	 evaluating	 its	
presence	 and	 impact	 on	 varying	 populations,	 and	 reviews	 the	 attempts	 for	 standardisation	 by	 the	
Strategic	Advisory	Group	of	Experts	Working	Group	on	Vaccine	Hesitancy.	Lastly,	 the	 literature	review	
identifies	gaps	in	the	literature,	and	suggests	filling	them	ideally	with	a	standardised	metric.	
	
The	manuscript	(Part	C)	is	presented	in	a	format	suitable	for	Vaccine	journal	submission.	The	manuscript	
includes	 a	 background,	 a	 description	 of	 the	methods	 used,	 and	 a	 presentation	 and	 discussion	 of	 the	
results	of	the	systematic	review.	
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Abstract	
BACKGROUND:	Vaccine	hesitancy	is	defined	by	the	World	Health	Organization	(WHO)	as	a	complex	and	
context	specific	delay	in	acceptance	or	refusal	of	vaccines	despite	availability	of	vaccination	services.	The	
reasons	why	individuals	hesitate	or	choose	not	to	vaccinate	are	variable	and	not	well	described,	and	the	
factors	contributing	to	vaccine	hesitancy	are	unclear.	Vaccine	hesitancy	influences	vaccine	coverage.	In	
order	 to	 achieve	high	 vaccination	 coverage	 and	develop	 strategies	 to	 target	 vaccine	hesitancy	 and	 to	
improve	vaccination	uptake,	 factors	contributing	to	vaccine	hesitancy	must	be	better	understood.	The	
factors	associated	with	vaccine	hesitancy	in	low	and	middle-income	countries	(LMICs),	specifically	on	the	
African	 continent,	 should	 be	 examined	within	 their	 own	 context	 in	 order	 to	 develop	 context-specific	
strategies	to	address	hesitancy.	AIM:	The	aim	of	this	review	is	to	describe	the	determinants	contributing	
to	vaccine	hesitancy	in	Africa.	METHODS:	A	systematic	review	protocol	for	the	study	was	developed	and	
registered	 in	 the	 PROSPERO	 International	 Prospective	 Register	 of	 systematic	 reviews	 (registration	
number	 CRD42016051699).	 The	 systematic	 review	 study	will	 search	 seven	 online	 databases	 for	 peer-
reviewed	papers	that	have	conducted	studies	 in	any	African	country.	Studies	 investigating	the	reasons	
why	participants	hesitate	to	vaccinate,	or	choose	to	delay	or	refuse	vaccination	of	themselves	or	their	
dependents	will	be	 included.	Studies	to	be	 included	 in	the	review	will	be	on	vaccine	hesitancy	against	
any	WHO	licensed	vaccines	as	of	2016.	Risk	of	bias	 for	 the	 included	studies	will	be	assessed	using	the	
CASP	tool.	Findings	will	be	reported	according	to	the	WHO's	Strategic	Advisory	Group	of	Experts	(SAGE)	
on	Vaccine	Hesitancy	which	categorises	three	broad	groups	of	factors	contributing	to	vaccine	hesitancy.	
The	findings	can	be	used	as	a	foundation	to	characterise	vaccine	hesitancy	as	well	as	to	develop	Africa-
specific	strategies	to	mitigate	the	impact	of	vaccine	hesitancy	on	vaccine	coverage.	
Keywords:	vaccine	hesitancy,	determinants,	immunisation,	vaccine,	SAGE,	Africa,	immunization	
	
Background	
In	 the	 last	 four	 decades,	 African	 countries	 have	 achieved	 steady	 progress	 in	 reducing	 vaccine	
preventable	diseases	(VPDs)	(1).	The	success	is	built	on	the	expanded	programme	on	immunisation	(EPI),	
a	platform	used	to	administer	vaccines	mainly	to	children	since	its	establishment	in	1974	(1).	
	
Recently,	 there	 are	 reports	 suggesting	 that	 vaccination	 coverage	 in	 many	 African	 countries	 has	
plateaued	at	suboptimal	 levels	(2,	3).	Many	factors	are	thought	to	contribute	to	the	observed	plateau,	
among	them:	 limited	access	to	vaccination	services,	 inadequate	resources	as	well	as	vaccine	hesitancy	
(1,	 4).	 Vaccine	 hesitancy	 is	 a	 complex	 and	 context	 specific	 delay	 in	 acceptance	 or	 refusal	 of	 vaccines	
despite	the	availability	of	vaccine	services	(5).	Not	only	does	vaccine	hesitancy	impact	those	making	the	
decision	 for	 themselves,	 but	 also	 those	 dependent	 on	others	 to	make	 the	 decision	 for	 them,	 such	 as	
children.	 Therefore,	 vaccine	 hesitancy	 has	 been	 associated	 with	 low	 compliance	 with	 vaccination	
schedules	 in	 some	 settings	 (4).	 Reports	 from	 developed	 countries	 show	 that	 vaccine	 hesitancy	 is	
increasing	 and	 could	 reverse	 some	 gains	 achieved	 through	 (6).	 Vaccine	 hesitancy	 is	 an	 under	 studied	
field,	 particularly	 so	 among	 African	 countries.	 It	 is	 possible	 that	 vaccine	 hesitancy	 contributes	 to	
suboptimal	vaccination	coverage	observed	among	many	African	countries.			
	
There	have	been	many	factors	and	reasons	(broadly	herein	referred	to	as	determinants)	described	to	be	
associated	with	 vaccine	hesitancy	 (7).	However,	 vaccine	hesitancy	 is	 poorly	 understood	 in	Africa.	Our	
systematic	review	study	describes	the	determinants	associated	with	vaccine	hesitancy	in	Africa.		
	
The	WHO,	through	the	Strategic	Advisory	Group	of	Experts	(SAGE)	on	Vaccine	Hesitancy	has	categorised	
determinants	associated	with	vaccine	hesitancy	 into	three	groups	of	 influences:	contextual	 influences,	
individual	and	group	influences,	and	vaccine/vaccination	specific	issues	(7).	Each	of	these	categories	has	
a	 number	 of	 subcategories	 that	 point	 to	more	 specific,	 individual-	 and	 community-level	 influences	 of	
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vaccine	hesitancy.	We	will	use	the	SAGE	categories	of	hesitancy	to	describe	the	determinants	associated	
with	vaccine	hesitancy	in	Africa.	
	
The	aim	of	this	review	is	to	describe	the	determinants	of	vaccine	hesitancy	in	Africa.	
	
While	 few	existing	strategies	have	been	designed	to	address	vaccine	hesitancy,	even	fewer	have	been	
evaluated	 for	 impact	 (8).	 Understanding	 the	 determinants	 of	 vaccine	 hesitancy	 is	 an	 important	 step	
towards	the	development	of	comprehensive	strategies	needed	to	improve	vaccination	uptake	in	African	
countries	(9).		
	
Study	objectives	
1.	Primary	objective	
To	identify	and	describe	the	determinants	of	vaccine	hesitancy	in	Africa.	
	
Study	eligibility	criteria	
We	will	use	participants,	intervention,	comparator,	and	outcome	(PICO)	to	structure	our	study	eligibility	
criteria.	
	
1.	Participants	
Persons	living	in	Africa	and	choosing	not	to	be	vaccinated	with	WHO-licensed	vaccines	as	at	December	
2016.	Persons	may	include	patients,	parents,	guardians,	caretakers,	children,	and	adolescents.	The	SAGE	
Working	Group	on	Vaccine	Hesitancy	defines	a	vaccine-hesitant	 individuals	as	"a	heterogeneous	group	
in	the	middle	of	a	continuum	ranging	from	total	acceptance	to	complete	refusal;	these	individuals	may	
refuse	some	vaccines,	but	agree	to	others;	delay	vaccines	or	accept	vaccines	but	are	unsure	of	doing	so"	
(7).		
	
2.	Study	settings	
Studies	conducted	in	any	country	on	the	African	continent,	with	no	date	restriction.	
	
3.	Intervention	
Provision	of	any	WHO-licensed	vaccines/immunisation	services	as	of	December	2016,	excluding	seasonal	
or	outbreak	vaccines	 (10).	Specific	vaccines	and	vaccine	preventable	diseases	 (VPDs)	 to	be	 included	 in	
this	study	will	be	all	WHO-licensed	vaccines.	See	Appendix	1	for	a	complete	list.	
	
4.	Comparator	
Not	applicable.	
	
5.	Outcome	
Determinants	of	vaccine	hesitancy	among	study	participants	as	defined	by	the	SAGE	Working	Group	on	
Vaccine	Hesitancy	Model	of	Determinants.		
	
6.	Study	designs	
Quantitative	studies	(randomised	controlled	trials,	controlled	before-and-after	studies,	interrupted	time	
series	 designs,	 cohort	 studies,	 case-control	 studies,	 cross-sectional	 studies)	 and	 qualitative	 studies	
(focus	group	discussions,	in-depth	interviews,	direct	observation,	case	studies,	ethnography,	and	action	
research)	 will	 be	 included	 in	 the	 searches.	 Only	 randomised	 control	 studies	 that	 specifically	 aim	 to	
address	vaccine	hesitancy	will	be	included.	Interventional	studies	such	as	clinical	trials	or	studies	testing	
vaccine	efficacy	or	effectiveness	and	not	designed	to	measure	the	determinants	of	vaccine	hesitancy	for	
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example	 will	 be	 excluded.	 Non	 peer-reviewed	 papers	 including	 grey	 literature	 will	 be	 excluded.	
Systematic	reviews	and	narrative	reviews	will	be	excluded.		
	
Methods	
This	 is	a	systematic	 review	study.	A	systematic	 review	protocol	 for	 the	study	has	been	developed	and	
published	 in	 the	 PROSPERO	 International	 Prospective	 Register	 of	 systematic	 reviews	
(http://www.crd.york.ac.uk/PROSPERO),	registration	number	CRD42016051699.		
	
1.	Search	strategy	
The	PICO	elements	will	be	used	to	build	a	search	strategy.	Databases	to	be	searched	include:	PubMed,	
Cochrane	 Central	 Register	 of	 Controlled	 Trials	 (CENTRAL),	 Scopus,	 Web	 of	 Science,	 World	 Health	
Organization	Library	Information	System	(WHOLIS),	Africa	Wide,	and	CINAHL.	Papers	of	any	publication	
date	will	be	included.	See	Appendix	2	for	full	search	strategy.	
	
2.	Study	selection	
Prior	 study	 selection,	 search	 strategy	 will	 be	 optimised	 in	 PubMed	 database.	 PubMed	 has	 the	 most	
extensive	and	comprehensive	search	engine	with	the	ability	to	also	search	for	medical	subject	headings	
(MeSH).	 Search	 strategy	 optimisation	 will	 include	 the	 first	 author	 applying	 the	 search	 query	 to	 get	
outputs,	and	screening	 titles	and	abstracts	 to	 identify	 ten	 relevant	 studies.	From	the	 relevant	 studies,	
the	first	author	will	read	full	articles	to	identify	any	key	terminologies	that	may	not	have	been	included	
in	 the	 first	 search	 and	 these	 new	 terms	 will	 be	 added.	 Additional	 optimisation	 will	 include	 testing	
sensitivity	 and	 specificity	 by	 systematically	 adding	or	 omitting	 synonymous	 search	 terms,	 followed	by	
the	assessment	of	the	outputs.		
	
Following	 optimissation	 of	 the	 search	 query,	 the	 first	 author	 will	 search	 all	 identified	 databases	 and	
import	 the	 results	 into	 EndNote	 citation	 manager.	 Duplicates	 will	 be	 removed	 and	 recorded	 for	 a	
PRISMA	diagram.	The	PRISMA	flow	chart	will	be	used	to	summarise	each	step	of	the	selection	of	studies	
for	the	review,	including	the	reasons	for	exclusion	of	studies.	
	
The	results	will	then	be	imported	into	a	MS	Excel	file	where	titles	and	abstracts	will	be	screened	by	the	
first	 author.	 Results	 will	 be	 excluded	 based	 on	 the	 inclusion	 and	 exclusion	 criteria,	 recorded	 for	 the	
PRISMA	diagram,	 and	 the	process	will	 also	be	 completed	and	 verified	by	 the	 second	author.	 Full	 text	
articles	of	the	remaining	papers	will	be	identified	by	the	first	author	and	shared	with	the	second	author	
to	 begin	 the	 data	 extraction	 process.	 Reference	 lists	 from	 the	 included	 studies	 will	 be	 screened	 for	
possible	relevant	studies.	
	
3.	Data	extraction	
Once	eligible	studies	have	been	selected,	 the	data	will	be	extracted	using	a	data	extraction	 form.	The	
data	extraction	form	will	be	piloted,	and	revised	if	necessary,	prior	to	extracting	data	from	the	full	text	
of	all	selected	studies.	The	final	data	extraction	form	will	be	completed	in	Excel	and	use	a	standardised	
code-frame.	The	first	author	and	two	supervisors	will	compare	their	data	extraction	forms	after	reading	
full	text	articles	in	order	to	compare	and	discuss	any	discrepancies.			
	
4.	Dealing	with	missing	data	
If	a	selected	study	is	found	to	have	missing	data,	the	study	correspondent	author	will	be	contacted	and	
requested	for	the	missing	data.	Any	missing	data	will	be	described	for	each	included	study	and	discussed	
to	identify	the	extent	to	which	the	results	of	this	review	may	be	altered.	
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5.	Assessment	of	the	risk	of	bias	
Risk	of	bias	for	the	selected	studies	will	be	assessed	using	a	critical	appraisal	tool	(CASP).	CASP	appraisal	
tools	 are	 the	 optimal	 tool	 for	 appraising	 the	 variety	 of	 study	 designs	 that	 will	 make	 up	 this	 review	
situated	within	the	field	of	public	health.	Critically	appraising	the	studies	used	in	this	review	will	ensure	
high	quality,	trustworthy	and	relevant	research	(11).	
	
Data	analysis	
1.	Quantitative	data	analysis	and	synthesis	
Quantitative	data	will	include	the	number	of	participants	per	study,	the	number	of	studies	per	country	
and	region	 (as	determined	by	MeSH	geographical	 terms),	among	other	variables	which	will	be	piloted	
during	the	data	extraction	process.	
	
2.	Qualitative	data	analysis	and	synthesis	
The	qualitative	data	will	be	extracted	using	qualitative	thematic	coding	within	the	data	extraction	form	
by	the	first	author	and	a	study	team	with	experience	in	qualitative	data	analysis.	The	outcomes	of	the	
studies	 will	 be	 coded	 and	 distributed	 into	 three	 groups	 of	 determinants	 based	 on	 the	 SAGE	
Determinants	 model	 (contextual	 factors,	 individual/group	 factors,	 and	 vaccine-related	 factors)	 (9).	
Distributing	 factors	 using	 the	 SAGE	 Determinants	 model	 will	 compliment	 research	 on	 interventions	
targeting	vaccine	hesitancy.	
	
Discussion	
This	review	will	identify	determinants	of	vaccine	hesitancy	in	various	countries	and	study	settings	within	
Africa.	 The	 identified	determinants	will	 be	discussed	with	 reference	 to	broader	 challenges	 for	 vaccine	
uptake,	 such	 as	misinformation,	 cultural	 values,	 inequality,	 economic	 development,	 political	 stability,	
and	literacy	levels.	Here,	synthesis	of	qualitative	research	is	valuable	as	it	will	bring	to	the	forefront	the	
critical	 issues	 affecting	 the	 reasons	why	 individuals	 choose	not	 to	 vaccinate,	which	 can	help	 to	 target	
future	 research	on	 interventions	 into	vaccine	hesitancy	and	 increase	vaccine	uptake	within	 an	African	
context.	
	
Study	strengths	and	limitations	
This	 review	 will	 use	 unbiased	 study	 methods	 to	 describe	 vaccine	 hesitancy	 in	 Africa.	 A	 research	
limitation	 and	 potential	 source	 of	 bias	 may	 be	 the	 decision	 to	 exclude	 non-peer	 reviewed	 studies.	
However,	due	to	the	evolving	nature	of	the	vaccine	hesitancy	field,	it	was	determined	that	unpublished	
studies	are	likely	to	show	higher	levels	of	non-standardisation	in	defining	vaccine	hesitancy,	hence	their	
exclusion.	 A	 potential	 limitation	 of	 this	 study	will	 be	 its	 generalisability,	 due	 to	 the	 unlikelihood	 that	
every	African	country	will	be	represented.	
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LITERATURE	REVIEW	
	
Introduction	
Vaccine	 hesitancy	 is	 complex	 and	 varies	 by	 context.	 Until	 recently,	 vaccine	 hesitancy	 did	 not	 have	 a	
standardised	definition	that	could	be	used	by	a	range	of	stakeholders.	While	there	is	abundant	literature	
describing	factors	or	predictors	of	low	uptake,	there	is	limited	research	specifically	aimed	at	identifying	
factors	of	vaccine	hesitancy,	even	 less	so	 in	African	countries.	The	Strategic	Advisory	Group	of	Experts	
(SAGE)	 Working	 Group	 (WG)	 on	 Vaccine	 Hesitancy	 has	 attempted	 to	 define	 vaccine	 hesitancy	 and	
develop	a	metric	to	guide	future	research,	which	can	be	targeted	to	fill	some	of	the	gaps	in	the	current	
research.	 The	 aim	 of	 this	 literature	 review	 is	 to	 describe	 vaccine	 hesitancy,	 the	 impact	 of	 vaccine	
hesitancy	on	vaccination,	the	current	literature	including	gaps	that	exist	to	date,	and	the	progress	of	and	
potential	for	standardisation	within	the	topic	of	vaccine	hesitancy.	
	
Search	strategy	
The	 search	 strategy	 for	 this	 literature	 review	 was	 adapted	 from	 the	 search	 strategy	 utilised	 for	 the	
accompanying	 systematic	 review	 on	 factors	 associated	with	 vaccine	 hesitancy	 in	 Africa	 (Appendix	 2).	
The	 search	 strategy	 conducted	 for	 this	 literature	 review	did	 not	 exclude	 review	 articles,	 and	was	 not	
limited	to	countries	within	Africa.	
	
Summary	and	interpretation	of	literature	
Success	of	vaccination	
Immunisation	 is	 one	 of	 the	 most	 successful	 and	 cost-effective	 public	 health	 interventions	 (4).	
Administration	of	vaccines	 is	a	preventative	measure	against	vaccine	preventable	diseases	(VPDs),	and	
immunisation	 is	 effective	 at	 both	 individual	 and	 community	 levels.	 There	 is	 overwhelming	 evidence	
demonstrating	the	benefits	of	 immunisation,	the	best	example	of	which	 is	 the	eradication	of	smallpox	
following	a	global	immunisation	campaign	led	by	the	World	Health	Organization	(WHO)	(1).	There	have	
also	been	significant	achievements	in	the	decline	of	diseases	such	as	tetanus,	diphtheria,	and	polio	(4).	
Maximum	 benefits	 from	 immunisation	 are	 achievable	 when	 individuals	 are	 receptive	 of	 vaccines.	 To	
reach	such	targets,	many	obstacles,	including	vaccine	hesitancy	must	be	overcome.	
	
The	significant	reduction	of	VPDs	can	be	attributed	to	efforts	of	a	number	of	global	health	organisations	
(2).	The	WHO	launched	the	Expanded	Programme	on	Immunisation	(EPI)	 in	1974,	which	aims	to	make	
safe	and	effective	vaccines	accessible	to	all	children	globally	(3).	There	have	been	successful	efforts	by	a	
number	of	 initiatives	 to	 increase	EPI	 coverage,	 such	as:	Universal	Childhood	 Immunisation,	 the	Global	
Alliance	for	Vaccines	and	Immunisation	(GAVI),	the	Millennium	Development	Goals,	and	most	recently,	
the	 Global	 Vaccine	 Action	 Plan	 (GVAP)	 (4)	 which	 has	 set	 a	 target	 to	 utilise	 national	 vaccination	
programmes	to	reach	90%	national	vaccination	coverage	by	2020	(5).	
	
Barriers	to	vaccination	
Despite	 these	 international	 efforts,	 coverage	 estimates	 have	 plateaued	 in	 recent	 years	 (6).	 In	 sub-
Saharan	Africa,	despite	WHO	Africa	Region's	 EPI	 strategic	plans	of	 action	during	 the	2000's,	 only	77%	
DTP3	(an	indicator	of	EPI	performance)	coverage	was	achieved	(4).	Overall	vaccination	coverage	in	sub-
Saharan	Africa	has	remained	constantly	below	that	of	other	regions,	and	countries	within	Africa	show	
large	disparities	in	coverage	(7).	
	
To	 prevent	 and	optimise	 control	 of	 VPDs,	 uptake	 rates	must	 be	 improved	 in	Africa.	 There	 have	 been	
significant	reductions	in	VPDs	where	high	vaccine	coverage	has	been	achieved	(2).	High	uptake	is	crucial	
because,	 unlike	medicines,	 vaccines	work	 at	 both	 the	 individual	 and	 community	 level	 (8).	 In	 order	 to	
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achieve	 community-level	 immunity,	 there	must	 be	 high	 uptake	 among	 individuals.	 Vaccine	 hesitancy	
contributes	to	low	rates	of	uptake,	and	is	an	important	challenge	to	overcome,	as	there	are	a	number	of	
determinants	which	can	vary	among	diverse	populations.	
	
While	 the	 impact	 of	 vaccine	 hesitancy	 on	 vaccine	 coverage	 is	 observed	 in	 both	 developed	 and	
developing	countries	alike,	the	factors	vary	according	to	context.	In	developed	countries	there	has	been	
a	paradigm	shift	from	increasing	access	to	increasing	acceptance	(9).	Given	the	long	history	of	vaccines	
in	developed	countries	such	as	the	United	States,	there	has	been	significant	increase	in	availability	and	
the	number	of	mandated	vaccines,	which	has	led	to	the	absence	of	VPDs	in	the	environment	and	in	the	
memories	of	various	stakeholders	(10).	Saad	Omer	reports	on	this	in	the	United	States,	where	a	major	
reason	 for	 vaccine	 refusal	 is	 a	 low	 level	 of	 concern	 about	 the	 risk	 of	 many	 VPDs	 (24).	 Developed	
countries,	such	as	the	United	Kingdom,	also	have	the	funding	available	to	monitor	vaccine	acceptance	
and	thus	anticipate	how	to	address	hesitancy	(25).	Where	uptake	is	low	in	developed	countries,	factors	
in	 play	 are	 understood	 to	 involve	 education,	 advocacy	 and	 acceptance	 (11).	 Developed	 countries	 are	
also	challenged	by	a	loss	of	public	trust	in	vaccines	(12).	Misinformation	and	anti-vaccine	movements,	as	
well	 as	 the	 communication	 and	 media	 environment	 which	 have	 promulgated	 and	 dramatised	 such	
movements,	are	also	prominent	factors	of	low	vaccine	uptake	that	are	found	to	a	much	lesser	degree	in	
developing	countries	(10,	13,	14).	
	
Considering	 the	 differences	 between	 developing	 and	 developed	 countries,	 context-specific	 strategies	
must	 be	 developed	 to	 improve	 vaccine	 uptake	 rates	 in	 Africa.	Developing	 countries,	 such	 as	 those	 in	
Africa,	experience	different	 factors	 contributing	 to	 the	observed	 low	vaccination	coverage.	Challenges	
such	 as	 competing	 health	 demands,	 poverty,	 inadequate	 knowledge	 on	 vaccination,	 religion,	 culture,	
weak	 health	 systems	 and	 underfunding,	 political	 will	 and	 competition	 for	 scarce	 resources	 (11)	 are	
prevalent	 in	 sub-Saharan	African.	 Education	of	 stakeholders,	 effective	 communication,	 and	 training	of	
health	workers	have	been	identified	as	strategies	that	can	have	a	positive	impact	on	vaccine	uptake	in	
sub-Saharan	Africa	(11).	An	increase	in	uptake	would	reduce	the	risk	of	morbidity	and	mortality	caused	
by	 VPDs	 and	 their	 complications	 among	 individuals	 as	 well	 as	 their	 communities	 by	 improving	 herd	
immunity.	 The	 increase	 in	human	capital	 that	 could	be	achieved	 improving	vaccine	 coverage	 is	 also	a	
cost-effective	strategy	to	strengthening	the	long-term	economic	prospects	of	these	developing	countries	
(15).	While	most	 factors	 contributing	 to	 vaccine	 hesitancy	 differ	 between	 developed	 and	 developing	
countries,	 some	 countries	 in	 Africa,	 such	 as	 South	 Africa,	 are	 beginning	 to	 see	 an	 increase	 in	 factors	
more	often	reported	in	developed	countries	thanks	to	advancements	in	communication	which	have	led	
to	anti-vaccine	movements	(3).	
	
Addressing	vaccine	hesitancy	
Vaccine	hesitancy	has	been	an	under	 researched	topic	without	standardised	terminologies	or	 themes.	
There	 is	much	variation	 in	 the	way	vaccine	hesitancy	 is	defined,	as	well	as	 the	aims	and	objectives	of	
literature	which	describes	factors	of	vaccine	hesitancy.	
	
The	 literature	search	has	 identified	numerous,	sometimes	competing,	definitions	of	vaccine	hesitancy.	
Peretti-Watel	 et	 al	 note	 the	 different	 attitudes	 within	 the	 field,	 such	 as	 those	 who	 consider	 vaccine	
hesitancy	 a	 long-standing	 phenomenon	 and	 attribute	 it	 to	 anti-vaccination	 attitudes,	 ignorance,	
misinformation	 or	 irrationality,	 versus	 those	who	 describe	 it	 as	 a	more	 recent	 attitude,	 distinct	 from	
anti-vaccination	 trends	 but	 correlated	 with	 knowledge	 and	 information	 (16).	 There	 was	 also	 some	
disjunction	 in	 defining	 vaccine-hesitancy	 as	 an	 empirical	 concept,	 as	 a	 general	mental	 representation	
derived	 from	 the	 perception	 of	 objects	 or	 interventions,	 versus	 the	 current	 definition	which	 covers	 a	
wide	range	of	heterogeneous	elements	(16).	
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There	is	a	gap	in	the	literature	that	explicitly	aims	to	describe	factors	contributing	to	vaccine	hesitancy.	
Among	 literature	 which	 has	 reported	 factors	 of	 vaccine	 hesitancy,	 doing	 so	 is	 not	 often	 the	 primary	
research	objective,	 and	 there	 is	 variation	 in	 the	ways	 the	 factors	 are	 reported.	 The	 literature	 yields	 a	
variety	 of	 synonymous	 terms	 that	 may	 or	 may	 not	 be	 considered	 vaccine	 hesitancy,	 including	
terminology	 such	 as	 "factors",	 "reasons",	 "determinants"	 or	 "motivations"	 for	 "rejection",	 "non-
acceptance",	"refusal"	or	"hesitancy"	of	vaccinations.	There	is	also	much	research	aiming	to	determine	
predictors	of	 vaccine	uptake,	 refusal	or	hesitancy	based	on	 socio-economic	determinants,	 rather	 than	
reasons	 as	 described	 by	 participants.	 While	 there	 may	 be	 overlap	 between	 studies	 in	 some	 of	 the	
reported	 factors,	 there	 is	 a	 lack	 of	 a	 standardised	 method	 to	 identify	 similar	 factors	 that	 could	 be	
targeted	by	interventions	to	address	vaccine	hesitancy.	
	
Among	 research	which	has	explicitly	 aimed	 to	describe	 factors	of	 vaccine	hesitancy,	 there	 is	 a	 lack	of	
standardisation	 in	 the	 way	 these	 factors	 are	 explained.	 A	 popular	 model	 utilised	 by	 some	 research	
focused	 on	 vaccine	 hesitancy	 is	 the	 Health	 Belief	 Model.	 The	 Health	 Belief	 Model	 "predicts	 that	 an	
individual’s	health	behavior	will	depend	on	 the	value	placed	on	achieving	a	goal	and	 the	belief	 that	a	
certain	 behavior	 will	 achieve	 that	 goal"	 (17).	 The	 Health	 Belief	 Model	 takes	 into	 consideration	 the	
individual's	perceived	susceptibility	and	severity	of	a	disease,	as	well	as	the	perceived	effectiveness	and	
benefits	 of	 the	 intervention.	While	 the	 Health	 Belief	Model	may	 be	 used	 to	 explain	 some	 factors	 of	
vaccine	 hesitancy	 at	 the	 individual	 level,	 it	 does	 not	 accurately	 take	 into	 account	 the	 influence	 of	
broader	 contextual	 factors	 (8).	While	 other	models,	 have	 been	 used	 in	 previous	 literature	 to	 explain	
vaccine	 hesitancy	 do	 share	 the	 common	 ground	 of	 viewing	 factors	 on	 a	 continuum,	 they	 do	 not	
adequately	 explain	 vaccine	 hesitancy	 at	 the	 population	 level,	 and	 cannot	 account	 for	 individuals	who	
may	accept	a	vaccine	but	remain	doubtful	and	hesitant	(18).	To	successfully	mitigate	vaccine	hesitancy	
and	 ultimately	 increase	 acceptance	 and	 uptake,	 there	 is	 a	 need	 for	 a	 further	 development	 and	
standardisation	within	the	field	of	vaccine	hesitancy.		
	
Standardising	“vaccine	hesitancy”	
The	SAGE	Working	Group	on	Vaccine	hesitancy	was	conceived	in	2012	with	the	aim	to	standardise	the	
field	 of	 vaccine	hesitancy,	 and	 to	 develop	 themes	 and	 tools	 to	 guide	 research	 and	 interventions.	 The	
SAGE	has	developed	a	definition	 for	vaccine	hesitancy,	based	upon	experience	 in	various	settings	and	
the	use	of	 the	 term	 in	 literature.	 The	 standardisation	 is	 expected	 to	minimise	 subjectivity	 and	ensure	
that	 clinicians,	 policy	 makers,	 researchers	 and	 other	 stakeholders	 would	 consistently	 use	 a	 standard	
term	to	cover	 the	 range	of	 factors	associated	with	vaccine	hesitancy	 (19).	According	 to	SAGE,	vaccine	
hesitancy	 refers	 to	 a	 "delay	 in	 acceptance	 or	 refusal	 of	 vaccines	 despite	 availability	 of	 vaccination	
services.	Vaccine	hesitancy	is	complex	and	context	specific,	varying	across	time,	place	and	vaccines.	It	is	
influenced	by	 factors	 such	as	 complacency,	 convenience	and	 confidence"	 (8).	While	 vaccine	uptake	 is	
sometimes	 affected	 by	 vaccine	 hesitancy,	 hesitancy	 does	 not	 always	 result	 in	 vaccine	 refusal,	 as	
individuals	who	 accept	 some	 vaccines	 can	 still	 be	 considered	hesitant	 if	 they	 reject	 other	 vaccines	 or	
have	some	doubts.	
	
In	 addition	 to	 defining	 vaccine	 hesitancy,	 SAGE	 has	 developed	 the	 Vaccine	 Hesitancy	 Determinants	
Matrix,	which	SAGE	describes	as	"useful	 for	guidance	on	development	of	vaccine	hesitancy	 indicators,	
survey	 questions,	 diagnostic	 tools,	 and	 strategies	 for	 intervention,	 and	 research"	 (8),	 and	 which	 was	
used	as	a	foundation	for	this	systematic	review	on	vaccine	hesitancy	 in	Africa	(Appendix	4).	The	SAGE	
Determinants	 matrix	 includes	 determinants	 identified	 from	 research	 studies	 and	 experiences	 of	 WG	
members	 and	 other	 experts.	 The	 SAGE	 Determinants	 Matrix	 is	 comprised	 of	 three	 main	 groups	 of	
influences	 of	 vaccine	 hesitancy:	 contextual	 influences,	 individual	 and	 group	 influences,	 and	 vaccine	
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specific	 issues.	 Each	 of	 these	 groups	 includes	 a	 range	 of	 determinants	 of	 vaccine	 hesitancy.	 Some	 of	
these	 determinants	 are	 comparably	 broad,	 "costs"	 for	 example,	 or	 another	 determinant	 covering	
"religion/culture/gender/socioeconomic"	factors	of	vaccine	hesitancy.		
	
An	important	point	of	the	SAGE	WG's	definition,	which	accounts	for	some	of	this	uncertainty	within	the	
topic,	 is	 that	vaccine	hesitancy	 is	 "present	when	vaccine	acceptance	 in	a	specific	 setting	 is	 lower	 than	
would	 be	 expected,	 given	 the	 availability	 of	 vaccination	 services"	 (8),	 thus	 a	 behavioral	 phenomenon	
that	 is	 not	 only	 vaccine	 and	 context	 specific,	 but	 also	measured	within	 the	 context	 of	 services	made	
available	and	 specific	 vaccination	goals	 (16).	 Furthermore,	 SAGE	defines	vaccine	hesitancy	as	 set	on	a	
continuum	 from	 total	 acceptance,	 to	 complete	 refusal,	 with	 vaccine	 hesitant	 individuals	 the	
heterogeneous	group	in	the	middle	(8,	19).		
	
While	SAGE	has	the	potential	to	be	the	driving	force	behind	standardisation	within	the	field	of	vaccine	
hesitancy,	 there	 is	 still	 a	 lack	 of	 clarity	 in	 some	 of	 SAGE	materials	 developed	 to	 date.	 There	 is	 noted	
difficulty	determining	vaccine	hesitancy	at	 the	population	 level	 for	numerous	reasons	 identified	 in	the	
literature.	One	reason	is	that	hesitancy	is	not	directly	related	to	uptake,	as	the	definition	includes	those	
who	have	accepted	vaccines	despite	having	significant	doubts	about	them	(18).	Furthermore,	there	can	
be	 variation	 in	 hesitancy	 according	 to	 the	 specific	 vaccine	 (18),	 such	 as	 concerns	 regarding	 the	 HPV	
vaccine	 as	 a	 new	 vaccine	or	 as	 a	 vaccine	 associated	with	 female	 reproduction	 (20,	 21).	 An	 important	
feature	of	vaccine	hesitancy	at	the	individual	level	is	the	perceived	risks	versus	benefits	of	vaccinations,	
which	occurs	at	the	individual	level	(22).	For	these	reasons,	Dubé	et	al	caution	drawing	a	general	picture	
of	vaccine-hesitant	characteristics	of	individuals	at	the	population	level	(18).		
	
While	there	is	difficulty	determining	characteristics	of	a	vaccine	hesitant	population,	some	literature	has	
emphasised	 the	 societal	 impact	 that	 vaccine	 hesitant	 attitudes	 of	 individuals	 can	 have	 on	 their	
communities.	Aside	 from	population-level	health	 impacts	of	 trends	 in	non-vaccination,	 such	as	 loss	of	
herd	 immunity,	 Abeysinghe	 refers	 to	 growing	 literature	 within	 the	 social	 sciences	 that	 suggests	 the	
perception	and	management	of	risk	occurs	at	both	societal	and	individual	levels	(22).	This	work	supports	
the	 argument	 that	 wider	 social	 representations	 of	 vaccination	 such	 as	 public	 discourse,	 not	 just	
individuals,	make	up	an	important	factor	underpinning	vaccine	hesitancy	(22).	This	does	not	permit	the	
generalisation	of	 a	 populations'	 apparent	 hesitancy	when	uptake	may	be	 low	across	 specific	 settings,	
vaccines	or	other	contexts,	but	rather	points	to	the	potential	impact	that	individuals'	may	have	on	their	
communities	when	others	are	presented	with	the	choice	to	vaccinate.	
	
There	 is	 emphasis	 within	 SAGE's	 definition	 of	 vaccine	 hesitancy	 regarding	 the	 issue	 of	 access.	While	
vaccine	hesitancy	may	be	present	in	low-uptake	situations,	situations	in	which	there	are	system	failures	
such	as	stock-outs	or	limited	availability	of	services,	vaccine	hesitancy	cannot	be	explained	as	the	main	
cause	of	 low	uptake	(19).	According	to	the	SAGE	WG,	these	situations	of	access	or	system	failures	 fall	
outside	of	the	scope	of	SAGE's	definition	of	vaccine	hesitancy	when	the	individuals	lack	the	opportunity	
to	accept	or	refuse	vaccines	(8).	This	explains	why	estimates	of	coverage	or	uptake	cannot	be	used	as	an	
indicator	of	vaccine	hesitancy.	Vaccine	hesitancy	is	indicated	by	the	choice	to	vaccinate	or	not,	based	on	
individuals'	assessment	of	risks	and	benefits	of	vaccination,	rather	 than	a	problem	of	 lack	of	access	to	
vaccination	services	or	the	greater	health	system	(22).	
	
Despite	clarification	on	these	issues	of	access	and	system	failures	by	emphasising	individual's	choice	in	
order	to	determine	if	vaccine	hesitancy	is	the	main	factor	of	non-vaccination,	SAGE	has	still	incorporated	
all	 of	 the	 above	 (poor	 availability,	 far	 travel	 distances,	 poor	 communication,	 etc.)	 into	 their	
Determinants	Matrix.	The	determinants	within	the	Matrix	related	to	access	are,	by	SAGE's	definition,	not	
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determinants	 of	 vaccine	 hesitancy	 because	 in	 most	 cases	 they	 preempt	 the	 opportunity	 to	 hesitate.	
However,	 there	 is	 also	 need	 for	 further	 clarification	 on	where	 issues	 of	 access	 fall	within	 the	 vaccine	
hesitancy	 continuum,	 as	 participants	 who	 decide	 the	 vaccination	 is	 not	 worth	 the	 time	 or	 effort	 of	
traveling	 a	 far	 distance	 could	 be	 categorised	 as	 vaccine-hesitant,	 whereas	 participants	 who	 accept	
vaccines	but	cannot	possibly	access	them	would	not	be.		
	
Gaps	in	the	literature	
In	addition	to	the	need	to	continue	to	develop	and	refine	a	standardised	metric,	there	are	several	gaps	
in	 research	specifically	on	vaccine	hesitancy	 that	may	suggest	strategies	 to	move	 forward.	 In	 terms	of	
research	methods,	there	is	a	disconnection	between	quantitative	and	qualitative	research,	missing	the	
opportunity	 to	 quantify	 the	 overall	 impact	 of	 vaccine	 hesitancy	 across	 different	 population	 strata	 in	
various	 settings	 (7).	 Especially	 in	 Africa	 where	 vaccine	 hesitancy	 is	 less	 associated	 with	 vaccine	
confidence,	 there	 is	 a	need	 to	determine	 the	weight	of	 other	determinants	 and	 structural	 barriers	 as	
factors	of	hesitancy	and	overall	uptake	(23).	Future	research	focusing	on	these	gaps	using	a	standardised	
toolset	will	help	to	mitigate	vaccine	hesitancy	and	increase	overall	uptake	of	vaccines,	but	there	remains	
a	need	for	research	assessing	interventions	already	in	place	to	address	concerns	(7).	
	
Conclusion	
Vaccine	hesitancy	 is	a	complex	and	context	specific	 issue	not	adequately	addressed	by	the	majority	of	
literature	 to	date.	Vaccine	hesitancy	has	 a	negative	 impact	on	 vaccination	 coverage	 globally,	which	 is	
crucial	 to	 the	success	of	vaccination	owing	 to	 the	nature	of	vaccines	working	at	a	community	 level	 to	
improve	health.	In	order	to	increase	vaccination	coverage	globally,	there	is	the	need	for	more	context-
specific	research	explicitly	aiming	to	identify	factors	of	vaccine	hesitancy.	This	research	is	especially	vital	
in	 African	 countries,	 where	 vaccination	 coverage	 rates	 have	 plateaued	 in	 recent	 years,	 and	 where	
factors	 of	 vaccine	 hesitancy	 differ	 from	 those	 experienced	 in	 other,	more	 developed	 regions.	 Future	
research	should	utilise	a	standardised	metric,	and	avoid	some	of	the	previously	used	terminology	that	
may	be	considered	synonymous	with	vaccine	hesitancy.	Increasing	the	amount	of	standardised	research	
in	 the	 field	 will	 illuminate	 context-specific	 needs	 and	 support	 future	 interventions	 targeting	 vaccine	
hesitancy	to	ultimately	improve	vaccination	coverage.	
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Abstract	
BACKGROUND:	Vaccine	hesitancy	 is	defined	as	a	 complex	and	context	 specific	delay	 in	acceptance	or	
refusal	of	 vaccines	despite	availability	of	 vaccination	 services.	 The	 reasons	why	 individuals	hesitate	or	
choose	 not	 to	 vaccinate	 are	 variable	 and	 not	well	 described,	 and	 the	 factors	 contributing	 to	 vaccine	
hesitancy	are	unclear.	AIM:	The	aim	of	 this	 review	 is	 to	 identify	and	describe	determinants	of	vaccine	
hesitancy	 in	 Africa.	 METHODS:	 A	 systematic	 review	 protocol	 for	 the	 study	 was	 registered	 in	 the	
PROSPERO	 International	 Prospective	 Register	 of	 systematic	 reviews	 (registration	 number	
CRD42016051699).	 A	 search	 was	 conducted	 in	 seven	 online	 databases	 for	 studies	 set	 in	 African	
countries	 in	 which	 participants	 described	 factors	 of	 vaccine	 hesitancy	 against	 any	 World	 Health	
Organization	 licensed	 vaccines	 as	 of	 December	 2016.	 Study	 and	 participant	 characteristics	 were	
extracted	 from	 the	 studies,	 and	 were	 extracted	 using	 the	 SAGE	 Determinants	 of	 Vaccine	 Hesitancy	
Matrix.	The	data	was	analysed	to	determine	factors	of	vaccine	hesitancy	overall,	and	stratified	by	study	
and	participant	characteristics.	RESULTS:	This	systematic	review	study	included	28	peer-reviewed	papers	
set	 in	 13	African	 countries,	which	were	 assessed	 for	 risk	 of	 bias	 using	 the	CASP	 tool.	Most	 factors	 of	
hesitancy	were	 individual	 and	 group	 influences,	 namely	 health	 system	 trust	 and	personal	 experience.	
Costs	 and	 a	 variety	 of	 contextual	 factors	 were	 also	 prominent	 factors	 of	 vaccine	 hesitancy	 among	
participants.	The	results	were	also	stratified	by	subgroups,	showing	differences	between	urban	and	rural	
settings,	programme	designs,	and	vaccines.	CONCLUSION:		Vaccine	hesitancy	is	one	factor	that	impacts	
vaccine	coverage.	In	order	to	achieve	high	vaccination	coverage	and	develop	strategies	to	target	vaccine	
hesitancy	and	to	 improve	vaccination	uptake,	 factors	contributing	to	vaccine	hesitancy	must	be	better	
understood.	The	results	suggest	that	determinants	of	vaccine	hesitancy	in	African	countries	are	primarily	
associated	with	access,	and	availability	of	resources	and	information.		The	results	underscore	the	need	
to	develop	context-specific	strategies	to	reduce	vaccine	hesitancy.		
Keywords:	vaccine	hesitancy,	determinants,	immunisation,	vaccine,	SAGE,	Africa,	immunization	 	
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Introduction	
Immunisation	is	one	of	the	most	successful	and	cost-effective	interventions	that	improve	public	health.	
Vaccines	are	preventative	measures	effective	at	both	 individual	and	community	 levels	to	protect	 from	
infectious	 diseases.	 The	 best	 example	 of	 the	 vaccine	 success	 may	 be	 the	 eradication	 of	 smallpox	
following	a	global	 immunisation	campaign	led	by	the	World	Health	Organization	(WHO)	(1).	 In	the	 last	
four	decades,	African	countries	have	achieved	steady	progress	in	reducing	vaccine	preventable	diseases	
(VPDs).	 The	 success	 is	 built	 on	 expanded	 programme	 on	 immunisation	 (EPI),	 a	 platform	 used	 to	
administer	vaccines	mainly	to	children	since	its	establishment	in	1974	(2).	
	
Overall	vaccination	coverage	in	sub-Saharan	Africa	has	remained	constantly	below	that	of	other	regions,	
and	countries	within	Africa	show	large	disparities	in	coverage	(3).	Recently,	there	are	reports	suggesting	
that	 vaccination	 coverage	 in	many	 African	 countries	 has	 plateaued	 at	 suboptimal	 levels	 (4,	 5).	Many	
factors	are	 thought	 to	contribute	 to	 the	observed	plateau,	among	 them:	 limited	access	 to	vaccination	
services,	inadequate	resources,	and	vaccine	hesitancy	(2,	3).	
	
Vaccine	hesitancy	 is	a	complex	and	context	 specific	delay	 in	acceptance	or	 refusal	of	vaccines	despite	
the	 availability	 of	 vaccination	 services	 (6).	 Not	 only	 does	 vaccine	 hesitancy	 impact	 those	making	 the	
decision	 for	 themselves,	but	also	 those	who	are	dependent	on	others	 to	make	 the	decision	 for	 them,	
such	as	children,	a	group	for	which	low	compliance	with	vaccination	schedules	has	been	associated	with	
vaccine	hesitancy	(3).	Reports	 from	developed	countries	show	that	vaccine	hesitancy	 is	 increasing	and	
could	reverse	some	gains	achieved	through	vaccination	 (7),	but	 factors	of	vaccine	hesitancy	vary	 from	
those	observed	in	developing	countries,	especially	those	in	Africa.	While	there	has	been	a	paradigm	shift	
away	from	increasing	access	and	towards	increasing	acceptance	in	developing	countries	(8),	developing	
countries	 face	 additional	 factors	 of	 hesitancy	 not	 limited	 to	 acceptance	 or	 access,	 such	 as	 competing	
health	 demands,	 poverty,	 and	 political,	 religious	 and	 cultural	 factors	 (9).	 In	 order	 to	 target	 vaccine	
hesitancy,	more	research	must	be	undertaken	to	increase	understanding	what	it	is	and	how	it	manifests,	
particularly	 so	among	African	 countries.	 This	 systematic	 review	 study	describes	 the	 factors	 associated	
with	vaccine	hesitancy	in	Africa.		
	
In	an	effort	to	standardise	the	field,	the	Strategic	Advisory	Group	of	Experts	(SAGE)	Working	Group	(WG)	
on	Vaccine	Hesitancy	has	categorised	a	number	of	factors	associated	with	vaccine	hesitancy	(identified	
via	 literature,	experiences	and	experts)	 into	a	Determinants	of	Vaccine	Hesitancy	Matrix	 (10,	11).	This	
systematic	review	defines	vaccine	hesitancy	in	concordance	with	SAGE,	and	uses	the	SAGE	Determinants	
of	Vaccine	Hesitancy	Matrix	to	report	the	factors	associated	with	vaccine	hesitancy	in	Africa.	
	
Research	 on	 vaccine	 hesitancy	 using	 a	 standardised	 metric,	 such	 as	 that	 defined	 by	 SAGE,	 has	 the	
potential	 to	 advance	 the	 field	 and	 design	more	 effective	 interventions.	While	 few	 existing	 strategies	
have	 been	 designed	 to	 address	 vaccine	 hesitancy,	 even	 fewer	 have	 been	 evaluated	 for	 impact	 (12).	
Understanding	 the	 factors	 contributing	 to	 vaccine	 hesitancy	 is	 an	 important	 step	 towards	 the	
development	 of	 comprehensive	 strategies	 needed	 to	 improve	 vaccination	 uptake	 in	African	 countries	
(13).	
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Methods	
A	 systematic	 review	protocol	 for	 the	 study	was	 registered	 in	 the	PROSPERO	 International	Prospective	
Register	 of	 systematic	 reviews	 (http://www.crd.york.ac.uk/PROSPERO),	 registration	 number	
CRD42016051699.	The	PICO	format	(participants,	intervention,	comparator,	and	outcome)	was	used	to	
structure	this	review.		
	
1.	Types	of	studies	selected	
Both	quantitative	studies	(randomised	controlled	trials,	controlled	before-and-after	studies,	interrupted	
time	series	designs,	cohort	studies,	case-control	studies,	cross-sectional	studies)	and	qualitative	studies	
(focus	group	discussions,	in-depth	interviews,	direct	observation,	case	studies,	ethnography,	and	action	
research)	 were	 eligible	 for	 inclusion.	 Interventional	 studies	 such	 as	 clinical	 trials	 or	 studies	 testing	
vaccine	 efficacy	 or	 effectiveness	 and	 not	 designed	 to	measure	 the	 outcomes	 associated	with	 vaccine	
hesitancy	 were	 excluded.	 Reviews	 (including	 systematic	 and	 narrative)	 editorials,	 and	 non-peer-
reviewed	papers,	including	grey	literature,	were	excluded.	
Studies	 needed	 to	 have	 investigated	 any	 WHO-licensed	 vaccines	 as	 of	 December	 2016,	 excluding	
seasonal	 or	 outbreak	 vaccines	 (14)	 (see	Appendix	 1	 for	 inclusion/exclusion	 criteria)	 were	 eligible	 for	
inclusion.	 The	 vaccine	was	 required	 to	 be	 available	 at	 the	 time	 of	 study,	 and	 participants	must	 have	
been	presented	with	the	vaccine	for	the	study	to	have	met	inclusion	criteria.	
	
2.	Study	Participants	
Persons	 living	 in	 Africa	 who	 were	 vaccine	 hesitant,	 choosing	 not	 to	 be	 vaccinated	 with	 any	 WHO-
licensed	vaccines	as	of	December	2016.	Participants	 included	patients,	parents,	 guardians,	 caretakers,	
children,	 and	 adolescents.	 The	 SAGE	 Working	 Group	 on	 Vaccine	 Hesitancy	 defines	 vaccine-hesitant	
individuals	as	"a	heterogeneous	group	 in	 the	middle	of	a	continuum	ranging	 from	total	acceptance	to	
complete	 refusal;	 these	 individuals	may	 refuse	 some	 vaccines,	 but	 agree	 to	 others;	 delay	 vaccines	 or	
accept	vaccines	but	are	unsure	of	doing	so"	(10).		
	
3.	Study	outcomes	
3.1	Primary	outcomes	
The	primary	study	outcomes	were	determinants	of	vaccine	hesitancy.	The	determinants	were	obtained	
from	 the	 reported	 participants'	 reasons	 for	 hesitating	 to	 vaccinate	 themselves	 or	 their	
children/dependents	were	identified	as	the	primary	outcome	of	this	study.		
	
4.	Study	settings	
Studies	 conducted	 in	 any	 country	on	 the	African	 continent,	with	no	date	 restriction,	were	eligible	 for	
inclusion	in	this	review.	
	
5.	Search	strategy	
Databases	searched	were:	PubMed,	Cochrane	Central	Register	of	Controlled	Trials	 (CENTRAL),	Scopus,	
Web	 of	 Science,	 World	 Health	 Organization	 Library	 Information	 System	 (WHOLIS),	 Africa	 Wide,	 and	
CINAHL.	Papers	of	any	publication	date	were	 included.	The	 search	 strategy	was	optimised	 in	PubMed	
database,	which	has	the	most	extensive	and	comprehensive	search	engine	with	the	ability	to	also	search	
for	medical	subject	headings	(MeSH).	Search	strategy	optimisation	involved	the	first	author	applying	the	
search	query	 for	outputs,	and	screening	 titles	and	abstracts	 to	 identify	 ten	 relevant	 studies.	From	the	
relevant	studies,	 the	 first	author	read	full	articles	 to	 identify	any	key	terminologies	that	may	not	have	
been	 included	 in	the	first	search	and	these	new	terms	will	be	added.	Additional	optimisation	 included	
testing	 sensitivity	 and	 specificity	 by	 systematically	 adding	 or	 omitting	 synonyms	 from	 search	 terms,	
followed	by	 the	 assessment	 of	 the	 outputs.	Once	 the	 search	 strategy	was	 optimised,	 the	 first	 author	
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searched	 all	 identified	 databases	 and	 imported	 the	 results	 into	 EndNote.	 The	 final	 search	 strategy	 is	
presented	in	Appendix	2.			
	
6.	Study	selection	
All	 search	 results	 were	 imported	 into	 EndNote	 and	 duplicates	 were	 removed.	 The	 results	 were	 then	
imported	into	an	MS	Excel	file	where	titles	and	abstracts	were	screened	by	the	first	author	to	determine	
whether	they	met	the	study	inclusion	criteria.	This	step	was	duplicated	by	the	last	author	(supervisor),	
and	any	disagreements	were	resolved	by	discussion.	A	search	for	full-texts	of	the	included	studies	based	
on	 the	 screening	 of	 titles	 and	 abstracts	was	 conducted	 by	 the	 first	 author.	 Studies	 that	 could	 not	 be	
found	were	requested	from	the	UCT	Health	Sciences	Library,	and	any	studies	that	could	not	be	found	by	
the	library	or	that	required	additional	payment	were	flagged	as	studies	for	which	the	full	text	could	not	
be	found.	Full	texts	were	read	by	both	the	first	and	last	authors	to	finalise	eligibility	and	inclusion,	and	
any	disagreements	were	resolved	by	discussion	or	further	clarification	by	contacting	the	study	authors.	
The	reference	 lists	 from	the	 included	studies	were	screened	for	potentially	eligible	studies	by	the	first	
author,	 first	 by	 titles	 and	 abstracts,	 then	 by	 full	 texts	 if	 they	 could	 be	 found.	 The	 PRISMA	 flow	 chart	
(Figure	1)	summarises	each	step	of	the	selection	of	studies	for	the	review.	
	
7.	Data	extraction	
Full	 texts	 of	 the	 eligible	 studies	 were	 read	 by	 the	 first	 author,	 and	 data	 was	 extracted	 using	 a	 data	
extraction	 form.	 The	 data	 extraction	 form	 was	 developed	 in	 MS	 Excel,	 and	 was	 piloted	 by	 the	 first	
author	with	the	first	ten	studies	and	any	necessary	adjustments	were	made.	The	data	extraction	form	
was	 consistent	 with	 outcomes	 in	 order	 to	 extract	 all	 relevant	 data	 from	 the	 full	 texts	 (the	 specific	
variables	are	discussed	below	in	the	analysis	section).	Codeframes	were	developed	by	the	first	author	to	
extract	both	quantitative	and	qualitative	data	from	the	texts	into	the	extraction	form.		
	
8.	Assessment	of	the	risk	of	bias	
Risk	of	bias	of	 the	 selected	 studies	was	assessed	using	a	 critical	 appraisal	 tool	 (CASP)	during	 the	data	
extraction	step.	CASP	appraisal	tools	are	robust	for	a	variety	of	study	designs,	and	was	used	to	score	the	
quality	of	the	studies	included	in	this	review	(15).	The	results	of	the	CASP	scoring	are	presented	in	Table	
2	in	the	appendix.	
	
9.	Quantitative	and	qualitative	data	analysis	
9.1	Quantitative	data	analysis	
The	 quantitative	 data	 extracted	 from	 each	 of	 the	 studies	 included	 the	 journal,	 year	 of	 publication,	
primary	objective	or	aim	of	 the	study,	 the	sample	size,	 the	study	design	and	data	collection	methods,	
the	country	and	study	setting,	the	vaccine	of	focus,	whether	the	vaccine	was	delivered	routinely	or	via	a	
campaign	or	other	activity,	where	the	vaccine	was	administered,	the	participants'	genders	and	ages,	and	
the	decision-maker	status	of	the	participants	(i.e.	whether	they	were	making	the	decision	for	themselves	
or	for	a	dependent).	Code	frames	were	developed	for	each	of	these	outcomes	(Appendix	3).	
Analysis	of	the	quantitative	data	was	conducted	by	the	first	author,	and	results	were	presented	with	a	
map	illustrating	the	number	of	studies	per	country	and	the	corresponding	vaccines	per	each	study.	
	
9.2	Qualitative	
Qualitative	data	was	consistent	with	the	primary	outcome	of	this	review,	which	were	the	determinants	
contributing	to	participants'	vaccine	hesitancy.	The	data	included	reasons	that	were	explicitly	identified	
by	the	studies,	or	that	were	mentioned	in	the	results	as	factors	of	non-vaccination.	Reasons	for	vaccine	
hesitancy	were	extracted	verbatim	as	 short	quotes	 into	an	MS	Excel	data	extraction	 form,	and	 coded	
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using	 thematic	 coding.	A	 single	 study	 could	be	assigned	multiple	 codes.	 If	more	 than	one	 reason	was	
stated	in	one	line,	the	line	was	duplicated	so	that	one	code	could	be	assigned	to	each	reason.	
	
The	SAGE	Determinants	of	Vaccine	Hesitancy	Matrix	was	the	guideline	for	the	codeframe	developed	and	
used	to	extract,	analyse	and	report	the	findings.	The	codeframe	was	further	adapted	from	code	frames	
used	 in	 review	 articles	 by	 SAGE	 (13)	 and	 Larson	 et	 al	 (16)	 to	 create	 sub-codes	 (or	 sub-determinants)	
where	the	qualitative	data	was	too	specific	to	fit	 into	some	broader	determinants	of	the	SAGE	Matrix.	
The	utilised	codeframe	is	included	in	Appendix	4.	
	
Analysis	of	the	qualitative	data	was	conducted	by	the	first	author,	and	involved	quantifying	the	number	
of	 responses	 corresponding	 to	 each	 sub-code	 (i.e.	 sub-determinant).	 The	 frequency	 of	 reported	 sub-
determinants	was	then	analysed	within	the	hierarchy	of	the	SAGE	Determinants	Matrix,	including	their	
corresponding	 SAGE	Determinants,	 as	well	 as	 SAGE's	 three	 groups	of	 determinants,	 to	determine	 the	
most	frequently	reported	factors	of	vaccine	hesitancy	among	the	selected	studies.	The	qualitative	sub-
determinants	 were	 then	 linked	 to	 the	 quantitative	 data	 of	 their	 corresponding	 studies,	 allowing	 for	
analysis	across	subgroups.	
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Results	
Characteristics	of	included	studies	
1.	Search	of	relevant	records	
The	 search	 yielded	 2497	 records	 from	 the	 seven	 identified	 databases.	 After	 removing	 duplicates,	 the	
titles	 and	 abstracts	 of	 2007	 records	 were	 screened;	 1773	were	 excluded	 based	 on	 eligibility	 criteria.	
After	 retrieving	 the	 full	 text	 of	 234	 potentially	 eligible	 records	 (21	 of	 which	 could	 not	 be	 found),	 23	
studies	met	the	inclusion	criteria.	After	screening	the	reference	lists	of	the	23	included	studies,	5	studies	
from	 the	 references	 list	 met	 the	 inclusion	 criteria,	 resulting	 in	 the	 28	 total	 studies	 included	 in	 this	
review.	The	search	of	relevant	records	is	represented	as	a	PRISMA	diagram	in	Figure	1.	Table	1	provides	
a	summary	of	the	included	studies.	
	
2.	Study	designs	and	methods	
The	majority	 (19/28	 i.e.	 67.9%)	 of	 studies	were	 of	 cross-sectional	 design	 (17-35).	 Seven	 (25%)	 of	 the	
studies	 described	 themselves	 as	 having	 qualitative	 study	 designs	 (36-40),	 two	 of	 which	 were	
ethnographies	(41,	42).	The	remaining	two	(7.1%)	studies	were	case-control	studies	(43,	44).	All	included	
studies	used	a	combination	of	surveys,	interviews,	and	focus	groups.	The	majority	(22/28	i.e.	78.6%)	of	
studies	were	published	between	2005	and	2015.	Combined,	a	total	of	32646	participants	(median	385.5,	
range	 40-1255)	 were	 represented	 in	 the	 included	 records.	 Table	 1	 provides	 a	 summary	 of	 included	
studies.	
	
2.1	Assessment	of	the	risk	of	bias	
CASP	(critical	appraisal	skills	programme)	critical	appraisal	tools	were	utilised	to	score	the	risk	of	bias	for	
each	of	 the	 studies	 included	 in	 this	 review.	CASP	appraisal	 tools	are	 robust	 for	 diverse	 types	of	 study	
designs	 (15).	 CASP	 tools	 designed	 to	 assess	 cross-sectional	 study	 designs,	 case-control	 studies,	 and	
qualitative	 studies	 were	 utilised.	 Using	 the	 CASP	 tool,	 none	 of	 the	 studies	 indicated	 a	 significant	
methodological	 flaw	as	the	average	percentage	score	was	72%,	with	the	 lowest	percentage	score	55%	
(Table	2).	
	
3.	Study	settings	
Out	of	54	African	countries	in	the	continent,	the	included	studies	were	from	13	countries	(Figure	2).	The	
majority	 (12/28	 i.e.	 42.9%)	 of	 studies	 were	 conducted	 in	 Nigeria.	 Uganda	 contributed	 three	 studies,	
Ethiopia	and	Tanzania	each	contributed	two	studies,	and	the	remaining	countries	(Benin,	Burkina	Faso,	
Egypt,	Gabon,	Guinea,	Mozambique,	South	Africa,	Sudan	and	Togo)	had	one	study	each.	
	
Whether	the	studies	were	conducted	in	urban	or	rural	settings	was	also	assessed,	as	this	could	influence	
the	reasons	for	vaccine	refusal.	Three	(10.7%)	studies	were	conducted	in	urban	settings,	two	(7.1%)	 in	
semi-urban/rural	 settings,	and	eight	 (28.6%)	 in	 rural	 settings.	Eight	 (28.6%)	studies	were	conducted	 in	
both	urban	and	rural	settings	within	their	countries,	and	the	remaining	seven	(25%)	did	not	specify	the	
study	setting	(Table	1).	
	
4.	Study	vaccines,	participants,	and	delivery	
4.1	Vaccines		
The	vaccines	of	the	included	studies,	as	well	as	the	study	participants'	roles	in	vaccine	decision-making	
were	assessed.	The	 included	studies	covered	six	vaccines:	 routine	childhood	(RC)	vaccines	 (that	varied	
by	 study	 based	 on	 the	 country-specific	 EPI),	 oral	 polio	 vaccine	 (OPV),	 human	 papilloma	 virus	 (HPV)	
vaccine,	oral	cholera	vaccine	(OCV),	Hepatitis-B	vaccine	(HepB),	and	Measles-Rubella	(MR)	(Table	1).	The	
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majority	(17/28,	60.7%)	of	studies	focused	on	routine	childhood	immunisation	(RC).	HPV	and	OCV	each	
contributed	two	studies	(7.1%),	and	there	was	one	study	each	(3.6%)	focusing	on	HepB	and	on	MR.		
4.2	Participants	decision-making	position	
Caregivers	 providing	 data	 on	 the	 hesitancy	 to	 vaccinate	 their	 children	 were	 the	 most	 represented	
participants	 (21/28,	 75%).	 Among	 OPV	 studies,	 three	 sampled	 caregivers,	 and	 two	 sampled	 both	
caregivers	 and	 independent	 decision-makers.	 One	 study	 focused	 on	 HPV	 vaccination	 sampled	
caregivers,	 while	 the	 other	 sampled	 both	 caregivers	 and	 independent	 decision-makers.	 One	 study	
focused	on	OCV	 sampled	 independent	 decision-makers,	while	 the	other	 sampled	both	 caregivers	 and	
independent	decision-makers.	The	two	studies	on	HepB	and	on	MR	both	sampled	independent	decision-
makers	as	participants	providing	data	on	their	vaccine-hesitancy.	
	
4.3	Delivery	methods	and	sites	
Vaccine	delivery	methods,	as	well	as	 the	 location	where	vaccines	are	administered,	may	 influence	the	
reasons	 for	 vaccine	 refusal	 (13).	 Therefore,	 the	 vaccine	 delivery	 strategies	 covered	 in	 the	 included	
studies	were	assessed.	Vaccine	delivery	methods	of	the	included	studies	were	recorded	either	as	part	of	
a	 vaccination	 campaign,	 or	 as	 part	 of	 routine	 immunisation	 activities.	 Campaigns	 included	 SIAs	
(supplemental	 immunisation	activities),	 IPDs	(immunisation	plus	days),	and	demonstration	projects.	12	
studies	(42.9%)	reported	hesitancy	towards	vaccines	delivered	routinely	(as	opposed	to	via	campaigns	or	
SIAs),	half	of	which	indicated	that	the	vaccines	were	delivered	at	health	centres.	Among	the	ten	studies	
on	 vaccine	 campaigns	 (35.7%),	 four	 reported	 vaccine	 delivery	 at	 home,	 three	 reported	 delivery	 of	
vaccines	in	a	school	or	university	setting,	and	two	reported	on	campaigns	that	set	up	vaccination	posts	
to	 deliver	 vaccines.	 The	 remaining	 six	 studies	 (21.4)	 did	 not	 specify	 the	 delivery	 sites	 and/or	 delivery	
methods.	
	
Reported	determinants	of	vaccine	hesitancy	
5.	Reported	determinants	overall	
The	 reported	 reasons	 for	 non-vaccination	 are	 reported	 in	 this	 review	 in	 congruence	 with	 the	 SAGE	
Determinants	Matrix	 (13).	The	codeframe	used	for	analysis	was	adapted	from	the	matrix	and	 includes	
additional,	 more	 specific	 "sub-determinants"	 of	 those	 in	 the	 SAGE	 model	 (16).	 See	 Appendix	 5	 for	
definitions	of	SAGE	determinants,	and	Appendix	4	for	the	adapted	SAGE	determinants	matrix	with	the	
added	“sub-determinants”.	Figure	3	 illustrates	 the	 frequencies	of	each	 reported	SAGE	determinant	of	
vaccine	 hesitancy.	 Figure	 4	 depicts	 the	 frequencies	 of	 all	 (305)	 reported	 sub-determinants	 of	 non-
vaccination	that	were	extracted	from	all	the	included	studies,	as	well	as	the	vaccine	types.		
	
5.1	Individual	and	group	influences	
Overall,	 individual	and	group	influences	made	up	the	majority	(169/305,	55.4%)	of	reasons	for	vaccine	
hesitancy.	A	more	detailed	analysis	of	the	individual	and	group	influences	showed	the	most	frequently	
reported	 determinants	 were	 "health	 system	 and	 providers-trust	 and	 personal	 experience"	 (61/169,	
36.1%)	 (Figure	3).	Within	 this	determinant,	 fear	of	 side	effects,	and	dissatisfaction	with	health	system	
(most	commonly	 including	 long	 lines	and	difficult	personal	 interactions,	but	also	a	 lack	of	resources	 in	
some	 instances)	 each	 contributed	 26.2%.	 Other	 significant	 determinants	 within	 individual	 and	 group	
influences	 were	 knowledge	 and	 awareness	 (43/169,	 25.4%),	 and	 beliefs/attitudes	 about	 health	
prevention	(24/169,	14.2%)	(Figure	4).	
	
5.2	Vaccine	specific	issues	 	
Vaccine	specific	issues	made	up	23.6%	(72/305)	of	factors	for	vaccine	hesitancy	overall.	Within	vaccine	
specific	 issues,	 the	 most	 frequently	 reported	 determinants	 were	 costs	 (35/72,	 48.6%),	 the	 design	 of	
 28	
vaccination	 programme	 or	 mode	 of	 delivery	 (17/72,	 23.6%),	 and	 unavailable	 vaccines	 due	 to	 supply	
(12/72,	 16.7%)	 (Figure	 3).	 Within	 costs,	 the	 interruption	 of	 time	 normally	 spent	 on	 other	 activities	
(17/35,	48.6%%)	and	the	inability	to	access	the	vaccine	site	due	to	the	handicap	or	illness	of	recipient	or	
caregiver	 (10/35,	 28.6%)	 were	 the	 most	 prominent	 sub-determinants.	 Within	 the	 design	 of	 the	
vaccination	programme	or	mode	of	delivery,	procedural	 issues	(including	 issues	with	vaccination	cards	
or	difficult	multi-stage	processes)	were	most	frequently	reported	(7/17,	41.1%)	(Figure	4).	
	
5.3	Contextual	influences	
Contextual	 influences	made	up	12.8%	(39/305)	of	all	 reported	reasons	 for	vaccine	hesitancy,	of	which	
religion/culture/gender/socioeconomic	(15/39,	38.5%),	geographic	barriers	(14/39,	35.9%),	and	political	
issues	(10/39,	25.6%)	were	the	most	frequently	reported	determinants	(Figure	3).	Husband	or	head-of-
household	 refusal	 (8/15,	 53.3%)	 and	 religion	 (5/15,	 33.3%)	 made	 up	 the	 majority	 of	 the	
religion/culture/gender/socioeconomic	determinant	(Figure	4).	
	
5.4	Other	reported	determinants	of	vaccine	hesitancy	
The	remaining	8.2%	(25/305)	of	reasons	reported	in	the	studies	were	categorised	as	"other"	(Figure	3).	
The	 determinants	 in	 this	 category	 included	 reasons	 that	 did	 not	 fit	 the	 SAGE	 determinants	 model,	
participants	 who	 reported	 already	 having	 the	 vaccine,	 non-specified	 issues	 of	 access	 or	 lack	 of	
opportunity,	and	reasons	categorised	by	the	studies	as	"other".	
	
6	Vaccine	hesitancy,	stratified	by	vaccines	
6.1	Routine	childhood	immunisations	(RC)	
The	majority	(17/28	i.e.	60.7%)	of	studies	focused	on	routine	childhood	immunisation	(RC),	all	of	which	
sampled	caregivers	as	participants	providing	data	on	their	hesitancy	to	vaccinate	their	children.	A	closer	
investigation	of	participants'	hesitancy	 towards	 routine	 immunisations	 found	that	 the	most	 frequently	
reported	determinants	 fell	within	 individual	 and	group	 influences	 (116/211,	55%)	 (Figure	3),	 of	which	
dissatisfaction	with	 the	health	system	(13/116,	11.2%),	motivation	 (forgetfulness,	disinterest,	 laziness)	
(12/116,	10.3%),	and	knowledge/awareness	(32/116,	27.5%)	made	up	the	majority	of	responses.	Costs	
were	a	major	 factor	within	vaccine	 specific	 issues	 (57/211,	27.0%),	especially	 the	 interruption	of	 time	
normally	spent	on	other	activities	(14/57,	24.5%),	and	the	vaccine	being	unavailable	at	the	delivery	site	
(11/57,	19.2%)	(Figure	3).	Geographic	barriers	made	up	57.1%	(12/21)	of	contextual	influences	inhibiting	
RI	uptake	among	participants.	
	
6.2	Oral	polio	vaccine	(OPV)	
Among	 studies	 looking	 at	OPV,	 vaccine	 safety	 (4/22,	 18.2%),	 and	 the	 belief	 that	 the	 vaccine	was	 not	
necessary	 (4/22,	 18.2%)	were	 the	most	 frequent	 sub-determinants	 of	 individual	 and	 group	 influences	
(Figure	 4).	 General	 disapproval	 of	 vaccines	 was	 reported	 more	 among	 OPV	 than	 any	 other	 vaccine	
included	 in	 this	 review.	 Prominent	 contextual	 influences	 (12/35,	 34.3%)	 of	 OPV	 refusal	 included	
politics/policies/mandates	(6/12,	50%)	and	religion/culture/gender/socioeconomic	(5/12,	41.7%)	(Figure	
3).	 Head	 of	 household	 refusal,	 a	 sub-determinant	 of	 religion/culture/gender/socioeconomic,	 was	
reported	more	among	OPV	refusal	than	refusal	of	other	vaccines	included	in	this	review.	
	
6.3	Oral	cholera	vaccine	(OCV)	
The	most	 frequently	 reported	 determinants	 of	 vaccine	 hesitancy	 among	OCV	 study	 participants	were	
dissatisfaction	with	health	system	(7/29,	24.1%)	(Figure	3),	of	which,	the	belief	or	fear	that	the	child	was	
too	young	to	receive	the	vaccine	(2/7,	28.5%)	was	reported	more	among	OCV	than	any	other	vaccine.	
Lack	of	 information	on	 the	 time	or	place	of	 the	vaccine	made	up	60.0%	of	 the	knowledge/awareness	
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determinant,	 and	 was	 reported	 more	 among	 OCV	 than	 any	 other	 vaccine.	 The	 interruption	 of	 time	
normally	spent	on	other	activities	was	the	most	frequent	vaccine-specific	 issue,	making	up	50%	of	the	
costs	determinant	(Figure	4).	
	
6.4	Measles-rubella	vaccine	(MR)	
The	most	frequently	reported	factor	of	vaccine	hesitancy	of	the	MR	vaccine	was	the	fear	of	side	effects	
or	infection	(2/10,	20%),	a	sub-determinant	of	SAGE's	"health	system	and	provider’s	trust	and	personal	
experience"	determinant,	within	individual/group	influences	(Figure	4).	
	
6.5	Human	papillomavirus	vaccine	(HPV)	
Among	participants	who	refused	the	HPV	vaccine,	the	fear	of	side	effects	and	the	distrust	or	fear	of	the	
vaccine's	effect	on	fertility	(3/13,	23.0%)	were	the	most	prominent	reasons	for	their	decision	(Figure	4).	
The	latter	determinant	was	reported	more	with	HPV	than	with	any	other	vaccine,	along	with	concerns	
with	the	vaccine	being	newly	introduced	(1/13,	7.7%).	
	
6.6	Hepatitis	B	vaccine	(HepB)	
For	 HepB,	 reasons	 categorised	 as	 "other"	 aside,	 all	 reported	 factors	 fell	 within	 individual	 and	 group	
influences.	Lack	of	knowledge	of	eligibility	or	when	to	receive	(1/7,	14.3%),	the	belief	that	the	vaccine	
was	 not	 necessary	 (1/7,	 14.3%),	 and	 fear	 of	 side	 effects	 (1/7,	 14.3%)	 were	 each	 mentioned	 as	
determinants	of	HepB	vaccine	hesitancy	(Figure	4).	
	
7.	Vaccine	hesitancy	by	study	settings	
A	closer	investigation	into	the	settings	in	which	the	included	studies	were	conducted	revealed	some	
differences	between	urban	and	rural	settings.	Factors	of	vaccine	hesitancy	stratified	by	study	settings	
are	presented	in	Figure	5.	
	
7.1	Rural	settings	
Within	individual	and	group	influences	in	rural	areas	(44/90,	48.9%),	"health	system	and	provider’s	trust	
and	personal	experience"	(16/44,	36.4%),	knowledge/awareness	(14/44,	31.8%)	were	the	most	
frequently	reported	determinants,	with	a	range	of	sub-determinants	reported	within	each	respectively.	
Beliefs/attitudes	about	health	and	prevention	(6/44,	13.6%)	also	had	a	significant	impact	on	the	
participant's	vaccine	hesitancy.	Vaccine-specific	issues	(29/90,	32.2%)	that	were	reported	more	in	rural	
settings	than	in	other	settings	were	the	reliability	and/or	source	of	vaccine	supply	(6/29,	20.7%),	and	the	
inability	to	access	the	vaccine	site	due	to	the	handicap	or	illness	of	recipient	or	caregiver	(7/29,	24.1%).	
Within	contextual	influences	(10/90,	11.1%),	geographic	barriers	(6/10,	60%)	was	more	frequently	
reported	in	rural	areas	than	in	any	other	setting.	
	
7.2	Urban	settings	
Not	unlike	 rural	 settings,	 "health	 system	and	provider’s	 trust	 and	personal	 experience"	was	 the	most	
prominent	determinant	among	urban	settings,	making	up	the	approximately	one	quarter	(5/21	23.8%)	
of	reported	reasons	for	vaccine	hesitancy.	Within	this	determinant,	 fear	of	side	effects	 (2/5,	40%)	and	
the	belief	that	too	many	vaccines	are	harmful	(1/5,	20%),	were	reported	more	in	urban	areas	than	in	any	
other	 setting.	Other	determinants	 that	were	 reported	more	within	urban	 settings	 than	other	 settings	
included	 the	 belief	 that	 vaccines	 could	 not	 be	 received	 when	 recipient	 sick	 (2/21,	 9.5%),	 mode	 of	
delivery	 (2/21,	 9.5%)	 (specifically	 procedural	 issues	 and	 limited	 opening	 times	 of	 vaccination	 sites,	
general	disapproval	of	vaccines	(1/21,	4.8%)	and	head	of	household	refusal	(1/21,	4.8%).	
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8.	Vaccine	Hesitancy	by	delivery	method	and	site	
Factors	of	vaccine	hesitancy	stratified	by	delivery	methods	and	delivery	sites	are	presented	in	Figure	6.	
	
8.1	Vaccination	campaigns	
Factors	 of	 vaccine	 hesitancy	 varied	 depending	 on	 whether	 the	 delivery	 method	 was	 a	 campaign	 or	
routine	 immunisation	 activities.	 Among	 studies	 which	 reported	 on	 vaccination	 campaigns,	 the	 most	
frequently	 reported	determinants	 fell	within	 individual	and	group	 influences,	 including	"health	system	
and	 provider’s	 trust	 and	 personal	 experience"	 (24/94,	 25.5%).	 Within	 this	 determinant,	 fear	 of	 side	
effects	 (7/24,	 29.2%)	 was	 reported	more	 among	 campaigns	 than	 among	 any	 other	 delivery	method.	
Vaccine	 specific	 issues	 (20/94,	 21.3%)	 were	 costs	 (8/20,	 40%)	 and	 the	 design	 of	 the	 programme	 or	
delivery	 (7/20,	 35%),	 including	 limited	open	hours	 and	being	absent	 from	 the	delivery	 site	during	 the	
campaign.	 Contextual	 issues	 among	 campaigns	 (16/94,	 17%)	 were	
religious/cultural/gender/socioeconomic	(6/16,	37.5%)	and	political	 (8/16,	50%).	Political	determinants	
were	reported	more	among	vaccination	campaigns	than	the	other	delivery	methods.	
	
8.2	Routine	immunisation	activities	
A	closer	 investigation	of	studies	reporting	on	routine	 immunisation	activities	found	that	 individual	and	
group	 influences	 made	 up	 most	 of	 the	 reasons	 for	 participants'	 vaccine	 hesitancy	 (64/113,	 56.6%).	
Within	this	group,	dissatisfaction	with	the	health	system	(9/113,	8%),	and	motivation	(8/113,	7.1%)	were	
most	 frequently	 reported.	 Among	 vaccine	 specific	 issues	 (27/113,	 24%),	 costs	 (15/113,	 13.3%)	
(specifically	 inability	 to	access	 the	vaccine	 site	due	 to	 the	handicap	or	 illness	of	 recipient	or	 caregiver	
(7/113,	 6.2%)),	 and	 the	 vaccine	 not	 being	 available	 (7/113,	 6.2%)	were	 the	most	 frequently	 reported	
factors	of	vaccine	hesitancy.	Geographic	barriers	also	made	up	7.1%	(8/113)	of	vaccine	hesitancy	factors	
among	studies	on	routine	vaccinations,	more	than	any	other	vaccination	delivery	method.	
	
8.3	Vaccination	delivery	sites	
Determinants	of	 vaccine	hesitancy	also	 varied	by	 vaccination	 site.	When	vaccinations	were	offered	at	
health	 facilities,	 the	 greatest	 determinant	 was	 "health	 system	 and	 provider’s	 trust	 and	 personal	
experience"	(19/91,	20.9%),	notably	dissatisfaction	with	the	public	health	system	(10/91,	11%).	Vaccine	
specific	 issues	 were	 greater	 when	 vaccines	 were	 delivered	 at	 health	 centers	 (26/91,	 28.6%).	 Costs	
(14/91,	15.4%)	(specifically	interruption	of	time	(6/91,	6.6%)),	the	design	of	the	vaccination	programme	
(6/91,	6.6%)	(notably	procedural	issues	(5/91,	5.5%)),	and	reliability	(6/91,	6.6%)	were	most	frequently	
reported.	
	
Contextual	influences	were	more	frequently	reported	(10/27,	37%)	when	vaccinations	were	delivered	at	
homes	compared	to	other	vaccination	sites.	Political	concerns	 (5/27,	18.5%),	 religion	 (2/27,	7.4%)	and	
head	of	household	refusal	(2/27,	7.4%)	were	most	frequently	reported	with	home-delivery,	while	costs	
were	of	least	concern	(except	when	the	recipient	was	not	at	home	during	delivery	(1/27,	3.7%)).		
	
When	vaccinations	were	delivered	at	vaccination	posts,	 in	or	close	to	villages	or	markets	 for	example,	
insufficient	information	on	the	time	and	place	of	the	vaccine	delivery	(3/29,	10.3%)	and	the	belief	or	fear	
that	the	child	was	too	young	to	receive	the	vaccine	(2/29,	7%)	were	more	frequently	reported	than	at	
other	 delivery	 sites.	 Costs	 (4/29,	 13.8%)	 were	 also	 frequently	 reported	 as	 determinants	 of	 vaccine	
hesitancy	among	vaccine	delivery	at	vaccination	posts.	
	
When	vaccinations	were	delivered	at	schools	or	universities,	fear	of	side	effects	(4/23,	17.4%)	was	more	
frequently	reported	than	at	other	vaccination	sites.	The	mode	of	administration,	frequently	reported	as	
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fear	of	injections	(2/23,	8.7%)	was	a	concern	that	was	unique	to	vaccines	delivered	at	school	compared	
to	other	vaccination	sites.		
	
9.	Vaccine	hesitancy	by	participants'	decision-making	position	
The	role	of	the	participant	in	decision	making,	whether	they	were	independently	making	the	decision	to	
vaccination	themselves,	or	making	the	decision	as	a	caregiver	for	their	child	or	a	dependent,	was	
expected	to	yield	different	factors	of	vaccine	hesitancy.	Factors	of	vaccine	hesitancy	stratified	by	
participants	decision-making	roles	are	presented	in	Figure	5.	
	
9.1	Independent	decision-makers	
Among	 participants	 who	 were	 making	 the	 independent	 decision	 to	 vaccinate	 themselves,	 the	 most	
frequently	reported	reasons	for	vaccine	refusal	were	fear	of	side	effects	(4/31,	12.9%),	the	interruption	
of	time	normally	spent	on	other	activities	(2/31,	6.5%),	limited	open	hours	(2/31,	6.5%),	and	distrust	in	
something	offered	for	free	(2/31,	6.5%).	
	
9.2	Caregivers	
Among	participants	who	were	caregivers	making	the	decision	to	vaccinate	their	child	or	dependents,	the	
most	 frequently	 reported	 reasons	 for	 vaccine	hesitancy	were	 "health	 system	and	provider’s	 trust	 and	
personal	experience"	(45/238,	18.9%)	(specifically	dissatisfaction	with	the	public	health	system	(14/238,	
5.9%)),	 knowledge	 and	 awareness	 (35/238,	 14.7%),	 costs	 (30/238,	 12.6%)	 (specifically	 interruption	 of	
time	 (14/238,	 5.9%),	 and	 inability	 to	 access	 due	 to	 illness	 or	 injury	 (9/238,	 3.8%)),	 [11]	 beliefs	 and	
attitudes	about	health	and	prevention	 (predominantly	 (12/238,	5%))	and	geographic	barriers	 (13/238,	
5.5%).			
	
9.3	Both	independent	decision-makers	and	caregivers	
Among	 studies	 in	which	both	 caregivers	 and	 the	 recipient	were	 vaccine	hesitant,	 factors	were	 largely	
associated	 with	 "health	 system	 and	 provider’s	 trust	 and	 personal	 experience"	 (10/36,	 27.8%),	
specifically	fear	of	side	effects	(3/36,	8.3%)	and	fear	the	vaccine	would	affect	fertility	(3/36,	8.3%).	Other	
concerns	 were	 of	 vaccine	 efficacy	 and	 safety	 (4/36,	 11.1%),	 and	 knowledge	 and	 awareness	 (4/36,	
11.1%).		
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Discussion	
While	this	review	could	not	include	studies	representing	each	African	country	due	to	non-availability	of	
the	 published	 relevant	 literature,	 it	 is	 significant	 that	 all	 of	 the	 African	 regions	 (as	 defined	 by	MeSH)	
have	been	represented	by	at	least	one	country.	Nearly	half	of	all	studies	(12/28,	43%)	were	conducted	in	
Nigeria.	A	closer	investigation	into	the	frequency	of	determinants	reported	by	the	participants	included	
in	 this	 review	revealed	no	mentions	of	historical	 factors	overall.	Political	determinants	were	not	more	
frequently	mentioned	in	Nigeria	than	in	any	other	country,	aside	from	two	mentions	of	the	belief	that	
the	government	should	allocate	resources	to	other	funds	rather	than	to	vaccination	services.	This	may	
be	explained	by	Nigeria	continuing	to	demonstrate	one	of	the	lowest	rates	of	childhood	immunisation	in	
the	 world,	 as	 well	 as	 the	 history	 of	 vaccination	 in	 Nigeria,	 including	 the	 2003	 boycott	 of	 polio	
vaccination,	and	the	subsequent	extensive	research	in	the	country	(19).	
	
	
Over	half	of	all	reasons	for	non-vaccination	reported	in	the	included	studies	fell	into	the	individual	and	
group	 influences	 group	 defined	 by	 SAGE.	 This	 reflects	 the	 number	 of	 determinants	 and	 sub-
determinants	being	greater	within	this	group	than	in	the	other	two	groups.	The	same	can	be	said	for	the	
most	 frequently	 reported	 determinant	 within	 this	 group,	 "health	 system	 and	 providers-trust	 and	
personal	 experience",	 which	 included	 a	 number	 of	 sub-determinants	 that	 fit	 best	 within	 this	
determinant.	One	of	the	more	frequently	reported	sub-determinants	of	"health	system	and	providers-
trust	 and	 personal	 experience"	 was	 dissatisfaction	 with	 the	 health	 system,	 which	 included	 difficult	
personal	 interactions	and	a	 lack	of	 resources	or	necessities	 at	health	 centres.	 The	wide	 range	of	 sub-
determinants	identified	within	the	determinants	of	the	individual	and	group	influences	group	sheds	light	
on	 the	need	 to	 further	define	determinants	 in	order	 to	 cover	 the	diverse	 factors	of	 vaccine	hesitancy	
that	were	found	by	this	review.	
	
Despite	 considerable	 support	 by	 GAVI	 to	 make	 vaccines	 more	 accessible	 within	 LMICs,	 costs	 were	 a	
major	factor	across	all	studies.	As	expected,	geographic	barriers	and	the	inability	to	access	vaccine	sites	
were	 determinants	 of	 vaccine	 hesitancy	 that	 were	 reported	 more	 frequently	 in	 rural	 than	 in	 urban	
settings.	Not	all	costs	were	explicitly	financial	in	terms	of	the	actual	cost	of	the	vaccine,	or	even	the	cost	
of	accessing	the	vaccine.	Costs	such	as	the	inability	to	access	due	to	inability	or	illness	(of	the	recipient	
or	caregiver),	or	the	interruption	of	time	normally	spent	on	other	activities	or	responsibilities,	might	be	
explained	 by	 what	 McKnight	 describes	 as	 the	 notion	 that	 vaccines	 are	 a	 low-involvement	 good,	
especially	 in	 subsistence-household	 economies,	 where	 vaccination	 requires	 a	 concerted	 effort	 and	
interruption	of	daily	demands	(42).		
	
Interventions	 to	 reduce	 vaccine	 hesitancy	 and	 increase	 uptake	 of	 vaccines	 must	 be	 context	 specific.	
Within	the	contextual	influences	group,	SAGE	has	included	the	communication	and	media	environment,	
religion,	 culture,	 gender,	 politics,	 and	 geography.	 While	 contextual	 factors	 will	 always	 be	 of	 great	
importance	 when	 addressing	 vaccine	 hesitancy,	 this	 group	 of	 determinants	 did	 not	 contribute	 a	
significant	number	of	determinants	of	vaccine	hesitancy	among	the	reviewed	studies.	A	few	conclusions	
can	be	drawn	from	the	findings	on	contextual	factors.	First,	whether	or	not	contextual	influences	are	a	
major	 factor	 of	 vaccine	 hesitancy,	 the	 results	 seem	 to	 indicate	 that	 the	 current	 interventions	 are	
appropriately	 context	 specific.	 Alternatively,	 it	 is	 possible	 that	 participants	 may	 not	 recognise	 these	
contextual	 barriers	 as	 the	 primary	 reason	 for	 their	 hesitancy.	 Second,	 it	 is	 clear	 that	more	 emphasis	
must	 be	 placed	 on	 individual	 and	 group	 influences,	 such	 as	 beliefs	 and	 attitudes	 about	 health	 and	
prevention,	and	trust	in	the	health	system,	as	well	as	on	vaccine-specific	issues	such	as	the	design	of	the	
programme	or	mode	of	delivery	and	costs.		
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The	results	suggest	that	addressing	vaccine	hesitancy	 in	Africa	should	be	prioritised	among	caregivers.	
This	is	likely	due	to	the	fact	that	nearly	all	populations	are	presented	with	the	option	to	receive	routine	
childhood	immunisations	at	some	point	during	the	early	years	of	their,	or	their	children’s,	lives.	This	is	in	
contrast	to	the	other	vaccines	included	in	the	study,	which	are	not	routinely	administered	to	the	general	
public,	either	because	they	are	often	presented	as	part	of	RC	immunisations	(such	as	OPV	and	MR),	or	
are	only	presented	to	or	considered	necessary	for	certain	populations,	such	as	OCV	in	certain	settings,	
HepB	 for	 health	 workers,	 and	 HPV,	 which	 is	 not	 only	 considered	 an	 adolescent	 vaccine	 but	 is	 also	
relatively	new	compared	to	the	others.	
	
Nearly	one-fifth	of	included	studies	focused	on	oral	polio	vaccine	(OPV),	all	of	which	were	conducted	in	
Nigeria,	 which	 can	 be	 attributed	 to	 the	 extensiveness	 of	 research,	 as	 well	 as	 a	 consequence	 of	 the	
historical	 issues	 in	 the	 country	 being	 specific	 to	 polio	 vaccinations.	 That	 the	 main	 determinants	 of	
vaccine	hesitancy	were	vaccine	safety,	general	disapproval	of	vaccines,	and	politics,	may	also	point	 to	
the	history	of	polio	vaccination	in	the	country.	Despite	these	results	being	significant	within	this	review,	
further	interpretation	is	not	merited	considering	global	plan	to	switch	from	OPV	to	IPV.	
	
While	only	two	of	the	included	studies	focused	on	oral	cholera	vaccine	(OCV),	it	is	significant	that	both	
were	conducted	on	campaigns	where	the	vaccine	was	delivered	at	vaccination	posts.	This	may	explain	
why	 the	determinants	of	 vaccine	hesitancy	among	OCV	 included	a	 lack	of	 information	on	 the	 time	or	
place	of	the	vaccine	(reported	more	among	OCV	than	any	other	vaccine),	and	the	interruption	of	time	
spent	on	other	activities.	Schaetti's	studies	of	perceptions	of	cholera	(45,	46),	which	sampled	the	same	
population	as	his	study	included	in	this	review,	may	explain	why	the	belief	that	the	child	was	too	young	
to	receive	the	vaccine	was	such	a	prominent	determinant	of	vaccine	hesitancy	in	the	presence	of	other,	
perhaps	more	familiar	and	less	invasive,	curative	and	preventative	methods	for	children	affected	by	or	
at	risk	of	cholera.		
	
HPV	 is	 a	 unique	 vaccine	not	only	because	 it	 is	 a	 newly	 introduced	 vaccine,	 but	 also	because	of	 some	
stigma	 surrounding	 it	 due	 to	 its	 relevance	 to	 adolescent	 sexual	 health	 and	 reproduction	 (47).	 The	
determinants	of	hesitancy	surrounding	HPV	reflected	these	unique	characteristics	of	the	vaccine,	as	fear	
of	the	vaccine's	effect	on	fertility	and	concerns	with	the	vaccine	being	newly	introduced	were	reported	
more	 among	 HPV	 studies	 than	 any	 other	 vaccine.	 These	 results	 are	 especially	 valid	 in	 the	 African	
context,	in	which	only	girls	are	currently	being	targeted	for	HPV	vaccination.	
	 	
Determinants	 of	 vaccine	 hesitancy	 varied	 between	 vaccination	 campaigns	 and	 routine	 immunisation	
activities,	as	well	as	between	different	delivery	 sites.	While	 issues	of	 communication	and	access	were	
reported	 at	 health	 facilities,	 contextual	 issues	 were	more	 apparent	 when	 vaccines	 were	 delivered	 at	
home.	 The	 results	 suggest	 that	 advocacy	 and	 communication	 of	 vaccination	 campaigns	 should	 be	
optimised	 to	 reduce	 some	 of	 the	 factors	 associated	 with	 vaccine	 hesitancy	 reported	 among	 the	
campaigns	included	in	this	review.	For	routine	immunisation	activities,	cost	reduction	and	interventions	
to	build	trust	between	health	care	workers	and	vaccine	recipients	should	be	considered.		
	
Study	strengths	and	limitations	
A	 strength	 of	 this	 review	 was	 the	 use	 of	 the	 SAGE	 Determinants	 of	 Vaccine	 Hesitancy	 Matrix,	 to	
characterise	the	reported	reasons	for	vaccine	hesitancy	among	the	participants	in	the	included	studies	
(Appendix	5).	The	codeframe	(Appendix	4)	was	adapted	from	other	studies	(16)	in	order	to	expand	on	
some	of	the	broader	determinants	in	the	SAGE	matrix.	
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The	outcomes	of	the	included	studies	were	broad,	ranging	from	identifying	reasons	for	non-vaccination,	
to	assessing	coverage,	to	evaluating	immunisation	programmes.	This	range	among	the	outcomes	of	the	
included	 studies	 can	 be	 attributed	 to	 the	 lack	 of	 a	 standard	 research	 approach	 to	 identify	 factors	
contributing	 to	 vaccine	 hesitancy.	 Therefore,	 most	 studies	 became	 eligible	 for	 inclusion	 when	
investigators	identified	reasons	participants	chose	not	to	vaccinate	(or	complete	vaccination),	which	was	
not	always	explicitly	stated	as	a	study	objective	despite	presenting	the	data.	Another	research	limitation	
and	potential	source	of	bias	may	be	the	decision	to	exclude	non-peer	reviewed	studies.	However,	due	to	
the	evolving	nature	of	the	vaccine	hesitancy	field,	it	was	determined	that	unpublished	studies	are	likely	
to	show	higher	levels	of	non-standardisation	on	defining	vaccine	hesitancy,	hence	the	exclusion.	
	
A	potential	limitation	of	this	study	is	the	coding	and	analysis	of	secondary	data.	Because	it	is	not	known	
what	surveys,	questionnaires	or	 interview	guides	were	used	to	collect	data	within	the	original	studies,	
there	is	the	potential	of	reduced	accuracy	when	coding	and	reanalysing	the	reported	results.	SAGE	has	
suggested	 that	 the	 Determinants	 Matrix	 be	 used	 as	 a	 guide	 for	 data	 collection	 in	 future	 studies	 on	
vaccine-hesitancy,	which	would	likely	minimise	this	limitation	within	this,	and	future,	reviews.	
	
Another	limitation	of	this	study	is	related	to	the	SAGE	Determinants	Matrix	due	to	contradictions	with	
the	definition	of	vaccine	hesitancy.	Despite	SAGE's	clarification	that	 issues	of	access	fall	outside	of	the	
scope	of	vaccine	hesitancy	when	participants	have	not	been	presented	with	the	choice	to	vaccinate	or	
not,	these	access	issues	are	included	in	SAGE's	Determinants	Matrix,	and	were	therefore	included	in	the	
codeframe	 used	 by	 this	 review.	 The	 decision	 to	 include	 issues	 of	 access	 in	 this	 review,	 despite	 the	
contradiction	 in	 the	SAGE	materials,	was	made	due	to	 the	context	of	vaccine	delivery	 in	Africa	and	to	
emphasise	the	necessary	improvement	of	access	to	vaccines.	There	is	a	need	for	further	clarification	on	
where	 issues	 of	 access	 fall	 within	 the	 vaccine	 hesitancy	 continuum,	 as	 participants	 who	 decide	 the	
vaccination	 is	not	worth	the	time	or	effort	of	 traveling	a	 far	distance	could	be	categorised	as	vaccine-
hesitant,	whereas	participants	who	accept	vaccines	but	cannot	possibly	access	them	would	not.	
	
There	is	also	a	need	for	further	clarification	of	other	determinants	that	may	not	meet	the	definition	of	
vaccine	hesitancy,	such	as	the	availability	or	supply	of	vaccines	at	delivery	sites.	For	example,	if	a	person	
accepts	a	vaccine,	 they	may	still	be	considered	vaccine-hesitant	 if	 they	do	not	have	confidence	 in	 the	
health	 system's	 ability	 to	 reliably	 keep	 stock,	 but	 they	 should	 not	 be	 considered	 hesitant	 if	 that	was	
actually	the	reason	for	their	non-vaccination.	
	
Conclusion	
Vaccine	 hesitancy	 in	 Africa	 is	 broad	 and	 has	 a	 range	 of	 determinants.	 Materials	 produced	 by	 SAGE,	
including	 their	definition	of	 vaccine	hesitancy	and	 their	matrix	of	determinants,	were	used	 to	analyse	
the	quality	 studies	which	were	 included	 in	 this	 review.	Despite	 strict	 inclusion	criteria,	 the	 results	are	
likely	 to	 be	 different	 if	 there	 were	 more	 studies	 that	 were	 primarily	 aimed	 at	 investigating	 vaccine	
hesitancy,	 especially	 if	 they	 also	 used	 the	 SAGE	 model.	 Well	 conducted	 future	 studies	 on	 vaccine	
hesitancy	in	Africa	are	likely	to	shed	more	light	on	the	topic,	and	if	a	model	such	as	SAGE's	becomes	the	
standardised	tool	for	such	studies,	future	reviews	on	vaccine	hesitancy	will	be	more	accurate.	
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Author Year Title Study	design Yes
Unsure/
Unclear No
Score			
(%	Yes)
Abd	Elaziz,	K.	M. 2010
A	measles	and	rubella	(MR)	catch-up	vaccination	campaign	in	an	Egyptian	
University:	Vaccine	uptake	and	knowledge	and	attitudes	of	students	 cross-sectional 8 3 0 73%
Abdulraheem 2011
Reasons	for	incomplete	vaccination	and	factors	for	missed	opportunities	among	
rural	Nigerian	children cross-sectional 11 0 0 100%
Babalola 2011
Maternal	reasons	for	non-immunisation	and	partial	immunisation	in	northern	
Nigeria cross-sectional 7 4 0 64%
Dugas 2009
Portrait	of	a	lengthy	vaccination	trajectory	in	Burkina	Faso:	from	cultural	
acceptance	of	vaccines	to	actual	immunization qualitative 9 1 0 90%
Ekunwe 1994 How	disease	prevention	fails	without	good	communication qualitative 6 4 0 60%
Eng 1991
The	acceptability	of	childhood	immunization	to	Togolese	mothers:	a	
sociobehavioral	perspective qualitative 8 2 0 80%
Fatiregun 2013
Assessing	full	immunisation	coverage	using	lot	quality	assurance	sampling	in	
urban	and	rural	districts	of	southwest	Nigeria	 cross-sectional 9 2 0 82%
Gammino 2014
An	Evaluation	of	Polio	Supplemental	Immunization	Activities	in	Kano,	Katsina,	
and	Zamfara	States,	Nigeria:	Lessons	in	Progress cross-sectional 8 3 0 73%
Helman 2004
Perceptions	of	childhood	immunisations	in	rural	Transkei	-	a	qualitative	study:	
original	article qualitative 8 2 0 80%
Ibekwe 2006 Hepatitis	B	vaccination	status	among	health	workers	in	Enugu,	Nigeria cross-sectional 7 4 0 64%
Itimi 2012
Community	participation	and	childhood	immunization	coverage:	a	comparative	
study	of	rural	and	urban	communities	of	Bayelsa	State,	south-south	Nigeria cross-sectional 9 2 0 82%
Jani 2008
Risk	factors	for	incomplete	vaccination	and	missed	opportunity	for	
immunization	in	rural	Mozambique cross-sectional 8 3 0 73%
LaMontagne 2011
Human	papillomavirus	vaccine	delivery	strategies	that	achieved	high	coverage	in	
low-	and	middle-income	countries	 cross-sectional 7 4 0 64%
Larson 2015 Measuring	Vaccine	Confidence:	Introducing	a	Global	Vaccine	Confidence	Index	 cross-sectional 7 4 0 64%
Loevinsohn 1989
Missed	opportunities	for	immunization	during	visits	for	curative	care:	practical	
reasons	for	their	occurrence cross-sectional 8 3 0 73%
Luquero 2013
First	Outbreak	Response	Using	an	Oral	Cholera	Vaccine	in	Africa:	Vaccine	
Coverage,	Acceptability	and	Surveillance	of	Adverse	Events,	Guinea,	2012	 cross-sectional 8 3 0 73%
Makoutode 2009 Impact	of	parental	attitudes	on	infant	vaccinal	coverage	in	Benin cross-sectional 8 3 0 73%
McKnight 2014
Designing	the	Expanded	Programme	on	Immunisation	(EPI)	as	a	service:	
Prioritising	patients	over	administrative	logic	 qualitative 8 2 0 80%
Michael 2014
An	Evaluation	of	Community	Perspectives	and	Contributing	Factors	to	Missed	
Children	During	an	Oral	Polio	Vaccination	Campaign	–	Katsina	State,	Nigeria	 cross-sectional 6 5 0 55%
Michael 2014
An	Assessment	of	the	Reasons	for	Oral	Poliovirus	Vaccine	Refusals	in	Northern	
Nigeria	 cross-sectional 8 3 0 73%
Mohammed 2014
Characteristics	of	persons	refusing	oral	polio	vaccine	during	the	immunization	
plus	days	–	Sokoto,	Nigeria	2011	 case-control 7 3 2 58%
Mohamud 2014
Immunization	coverage	of	12–23	months	old	children	and	associated	factors	in	
Jigjiga	District,	Somali	National	Regional	State,	Ethiopia cross-sectional 10 1 0 91%
Murele 2014 Vaccine	perception	among	acceptors	and	non-acceptors	in	Sokoto	State,	Nigeria	 qualitative 6 4 0 60%
Schaetti	 2012
Improving	Community	Coverage	of	Oral	Cholera	Mass	Vaccination	Campaigns:	
Lessons	Learned	in	Zanzibar	 cross-sectional 7 4 0 64%
Schwarz 2009
Reasons	for	non-adherence	to	vaccination	at	mother	and	child	care	clinics	(MCCs)	
in	Lambaréné,	Gabon qualitative 9 1 0 90%
Tugumisirize 2002
Missed	opportunities	and	caretaker	constraints	to	childhood	vaccination	in	a	
rural	area	in	Uganda cross-sectional 7 4 0 64%
Vonasek 2016
Do	Maternal	Knowledge	and	Attitudes	towards	Childhood	Immunizations	in	
Rural	Uganda	Correlate	with	Complete	Childhood	Vaccination? cross-sectional 9 2 0 82%
Watson-Jones 2012
Reasons	for	Receiving	or	Not	Receiving	HPV	Vaccination	in	Primary	Schoolgirls	in	
Tanzania:	A	Case	Control	Study	 case-control 7 5 0 58%
72%
Study	Details CASP	Results
Average	Score
Table 2: CASP Scores
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Figure	3: Reported	determinants	of	vaccine	hesitancy	
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Figure 5: Reported sub-determin nts of vaccine hesitancy, by participant and setting
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Appendix 1: Inclusion/exclusion criteria 
 
Participants patients, parents, guardians, teachers/educators, elders, or adolescents, living in an African 
country, who are presented with the opportunity to make a decision to receive a WHO-qualified 
vaccine (either as an independent decision-maker for themselves or as a caregiver or their child 
or dependent)  
Interventions vaccines, immunisations, or inoculations, including maternal vaccines/immunisations, 
vaccine/immunisation programmes or campaigns 
Included WHO-
qualified 
Vaccines and 
VPDs (WHO, 
2017)  
BCG HPV Polio Vaccine - Oral (OPV) 
Bivalent Types 1 and 3 
cholera: inactivated oral Japanese Encephalitis Vaccine 
(Inactivated) 
Polio Vaccine - Oral (OPV) 
Monovalent Type 1 
Diphtheria-Tetanus Japanese Encephalitis Vaccine 
(live, attenuated) 
Polio Vaccine - Oral (OPV) 
Monovalent Type 2 
Diphtheria-Tetanus (reduced 
antigen content) 
Measles Polio Vaccine - Oral (OPV) 
Monovalent Type 3 
Diphtheria-Tetanus-Pertussis 
(acellular) 
Measles and Rubella Polio Vaccine - Oral (OPV) 
Trivalent 
Diphtheria-Tetanus-Pertussis 
(acellular)-Hepatitis B-
Haemophilus influenzae type b-
Polio (Inactivated) 
Measles, Mumps and Rubella Rabies 
Diphtheria-Tetanus-Pertussis 
(whole cell) 
Meningococcal A Conjugate Rotavirus 
Diphtheria-Tetanus-Pertussis 
(whole cell)-Haemophilus 
influenzae type b 
Meningococcal A Conjugate 
(paediatric) 
Rubella 
Diphtheria-Tetanus-Pertussis 
(whole cell)-Hepatitis B 
Meningococcal A+C Tetanus Toxoid 
Diphtheria-Tetanus-Pertussis 
(whole cell)-Hepatitis B-
Haemophilus influenzae type b 
Meningococcal ACYW-135 
(conjugate vaccine) 
Typhoid (Polysaccharide) 
Haemophilus influenzae type b Meningococcal ACYW-135 
(polysaccharide) 
Yellow Fever 
Hepatitis A (inactivated) Pneumococcal (conjugate)  
Hepatitis B Polio Vaccine - Inactivated 
(IPV) 
 
Comparison / 
Outcome 
reasons or factors of: acceptance, refusal, hesitancy, or anti-vaccination (as defined by participant 
who refused) 
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Appendix 2: Search terms and strategy 
"PICO" Terms MeSH Terms 
P Participants patient* OR parent* OR guardian* OR 
teacher OR educator OR adolescen* 
OR elder* 
"Patients"[Mesh] OR "Parents"[Mesh] OR 
"Legal Guardians"[Mesh] OR "School 
Teachers"[Mesh] OR "Adolescent"[Mesh] 
Setting Africa* OR “South* AND Africa*” OR 
“West* AND Africa*” OR “East* AND 
Africa*” OR “North* AND Africa*” OR 
“Central AND Africa*” OR “Sub 
Saharan” OR Sub­Saharan OR 
Subsaharan OR Algeria OR Angola OR 
Benin OR Botswana OR “Burkina 
Faso” OR Burundi OR Cameroon OR 
“Cape Verde” OR “Central African 
Republic” OR CAR OR Chad OR 
Comoros OR Congo OR “Democratic 
Republic Of Congo” OR “Republic 
Congo” OR Zaire OR DRC OR Djibouti 
OR Egypt OR “Equatorial Guinea” OR 
Eritrea OR Ethiopia OR Gabon OR 
Gambia OR Ghana OR Guinea OR 
“Guinea Bissau” OR “Ivory Coast” OR 
“Cote D'ivoire” OR Kenya OR Lesotho 
OR Liberia OR Libya OR OR 
Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR 
Morocco OR Mozambique OR 
Moçambique OR Mocambique OR 
Namibia OR Niger OR Nigeria OR 
Reunion OR Réunion OR Rwanda OR 
“Sao Tome” OR “São Tomé” OR “São 
Tomé AND Príncipe” OR Senegal OR 
Seychelles OR “Sierra Leone” OR 
Somalia OR “South Africa” OR “South 
Sudan” OR Sudan OR Swaziland OR 
Tanzania OR Tanganyika OR Togo OR 
Tunisia OR Uganda OR “Western 
Sahara” OR Zambia OR Zimbabwe 
 
"Africa" [Mesh] OR "Africa South of the 
Sahara"[Mesh] OR "Africa, Central"[Mesh] OR 
"Cameroon"[Mesh] OR "Central African 
Republic"[Mesh] OR "Chad" [Mesh] OR 
"Congo"[Mesh] OR "Democratic Republic of 
the Congo" [Mesh] OR "Equatorial 
Guinea"[Mesh] OR "Gabon"[Mesh] OR 
"Africa, Eastern"[Mesh] OR "Burundi"[Mesh] 
OR "Djibouti"[Mesh] OR "Eritrea" [Mesh] OR 
"Ethiopia"[Mesh] OR "Kenya"[Mesh] OR 
"Rwanda"[Mesh] OR "Somalia"[Mesh] OR 
"South Sudan"[Mesh] OR "Sudan"[Mesh] OR 
"Tanzania"[Mesh] OR "Uganda"[Mesh] OR 
"Africa, Southern"[Mesh] OR "Angola"[Mesh] 
OR "Botswana"[Mesh] OR "Lesotho"[Mesh] 
OR "Malawi" [Mesh] OR 
"Mozambique"[Mesh] OR "Namibia"[Mesh] 
OR "South Africa" [Mesh] OR 
"Swaziland"[Mesh] OR "Zambia"[Mesh] OR 
"Zimbabwe" [Mesh] OR "Africa, 
Western"[Mesh] OR "Benin"[Mesh] OR 
"Burkina Faso" [Mesh] OR "Cape 
Verde"[Mesh] OR "Cote d'Ivoire"[Mesh] OR 
"Gambia" [Mesh] OR "Ghana"[Mesh] OR 
"Guinea"[Mesh] OR "Guinea-Bissau" [Mesh] 
OR "Liberia"[Mesh] OR "Mali"[Mesh] OR 
"Mauritania"[Mesh] OR "Niger"[Mesh] OR 
"Nigeria"[Mesh] OR "Senegal"[Mesh] OR 
"Sierra Leone"[Mesh] OR "Togo"[Mesh] OR 
"Africa, Northern"[Mesh] OR "Algeria"[Mesh] 
OR "Egypt"[Mesh] OR "Libya"[Mesh] OR 
"Morocco" [Mesh] OR "Tunisia"[Mesh] 
Intervention General vaccin* OR immuni* OR innoculat* OR 
"maternal vaccin*" 
"Vaccination"[Mesh]) OR 
"Immunization"[Mesh] OR "Vaccines"[Mesh] 
OR "Immunization Programs"[Mesh] OR 
"Organization and Administration"[Mesh] 
Comparison 
/ Outcome 
 accept* OR hesit* OR uptake OR 
refus* 
"Vaccination Refusal"[Mesh] OR "Anti-
Vaccination Movement"[Mesh] 
Filters Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, 
Comparative Study, Clinical Trial, Phase IV, Controlled Clinical Trial, Interview, Journal 
Article, Multicenter Study, Observational Study, Randomized Controlled Trial, Humans 
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Search Strategy: 
Search #1 = [Participants: Terms] 
Search #2 = [Participants: MeSH Terms] 
Search #3 = #1 OR #2 
Search #4 = [Setting: Terms] 
Search #5 = [Setting: MeSH Terms] 
Search #6 = #4 OR #5 
Search #7 = [Intervention: Terms] 
Search #8 = [Intervention: MeSH Terms] 
Search #9 = #7 OR #8 
Search #10 = [C/O: Terms] 
Search #11 = [C/O: MeSH Terms] 
Search #12 = #10 OR #11 
Final Search (#13) = #3 AND #6 AND #9 AND #12, apply filters 
 
Databases: 
PubMed 
Cochrane (CENTRAL) 
Scopus 
Web of Science 
CINAHL 
Africa Wide 
WHOLIS 
 
 
 
 
479
PubMed
r e ( E TRAL)
Web of Science
CINAHL
Africa Wide
WHOLIS
- Searched 19 Jan 2017
- Searched 19 Jan 2017
- Searched 20 Jan 2017
- Searched 20 Jan 2017
- Searched 20 Jan 2017
- Searched 20 Jan 2017
- Searched 26 Jan 2017
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Appendix 3: Quantitative codeframe 
 
Intervention (Vaccine) Delivery Site  Delivery Method 
Code Description Code Description Code Description 
1 routine childhood 1 not specified 1 not specified 
2 measles rubella (MR) 2 home, door-to-door 2 campaign 
3 HPV 3 health facility 3 routine 
4 polio (OPV) 4 school/university 4 RCT 
5 cholera (OCV) 5 vax post/site 5 SIA (supplemental) 
6 Hepatitis B  
 
  
 
  
Urban/Rural Gender Age 
Code Description Code Description Code Description 
1 not specified 1 both/not specified 1 not specified 
2 Rural 2 male 2 maternal 
3 Semi 3 female 3 infant 
4 Urban 
 
  4 child 
5 both rural and urban 
 
  5 adolescent  
  
 
  6 adult 
Study Design/Methods Literacy / Education Participant's decision role 
Code Description Code Description Code Description 
1 randomised controlled trials 1 not specified / 
multiple/various 
1 Independent decision-maker 
2 controlled before and after 2 primary/basic education 2 caregiver (decision-making 
for child/dependent) 
4 cohort 3 secondary education 3 Both (caregiver and child) 
5 case-control 4 tertiary/university 
education 
5 not specified 
6 cross-sectional 5 high levels of illiteracy in 
population 
6 both as independent 
decision-makers, and as 
caregivers 
7 focus group 6 medium levels of literacy 
 
  
8 interview (in-depth) 7 low levels of illiteracy 
 
  
10 case study 
 
  
 
  
11 ethnography 
 
  
 
  
13 qualitative 
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Code Sub-determinant SAGE	Determinant SAGE	Group
1 contextual	influences	(general/other) contextual	influences	(general/other)
2 communication	&	media	environment
2.1 access	to	information
2.2 mass	media	(use	and	influence)
3 influential	leaders,	gatekeepers	and	anti-/pro-vaccination	lobbies influential	leaders,	gatekeepers	and	anti-/pro-vaccination	lobbies
4 historical	influences historical	influences
5 religion/culture/gender/socioeconomic
5.1 Religion
5.2 Culture
5.3 Gender	(of	dependent)
5.4 Gender	(of	independent)
5.5 Husband	or	head-of-household	refusal
6 politics/policies/mandates
6.1 government	involvement,	interference
6.2 distrust	in	something	offered	for	free
6.3 belief	govt	should	allocate	resources	to	other	areas	(not	vax)
7 geographic	barriers geographic	barriers
8 pharmaceutical	industry pharmaceutical	industry
9 individual/group	influences	(general/other) individual/group	influences	(general/other)
10 experience	with	past	vaccination experience	with	past	vaccination
11 beliefs/attitudes	about	health	and	prevention
11.1 attitude
11.2 beliefs
11.3 motivation	(forgetfulness,	disinterest,	laziness)
11.4 practice	(general	non-use	of	health	services)
11.5 practice	(use	of	traditional/alternative	practices)
11.6 practice	(general	disapproval	of	vaccines,	no	detailed	reasons)
12 knowledge/awareness
12.1 vaccination	knowledge	(whether	additional	doses	are	required,	
eligibility/age/when	to	receive)
12.2 general	health	knowledge
12.3 myths/rumours
12.4 belief	that	vax	cannot	be	received	when	recipient	is	sick
12.5 insufficient	informaiton	on	time/place	of	vax/campaign
13 health	system	and	providers-trust	and	personal	experience
13.1 satisfaction	with	public	health	system,	difficult	personal	inteactions,	
symbolic	violence,	lack	of	resources/necesities	(i.e.	water)	at	facilities
13.2 distrust/fear	vaccine	due	to:	side	effects	(fear)
13.3 distrust/fear	vaccine	due	to:	infertility	(fear)
13.4 distrust/fear	vaccine	due	to:	belief	it	will	encourage	promiscuity
13.5 distrust/fear	vaccine	due	to:	beliefs	too	many	injections	are	harmful
13.6 distrust/fear	vaccine	due	to:	belief	child	too	young	to	receive
13.7 vaccinators	absent
13.8 long	wait,	delays,	crowds	at	delivery	site
14 risk/benefit	(perceived,	hueristic)
14.1 susceptibility	to	disease
14.2 disease	severity
14.3 vaccine	safety
14.4 vaccine	efficacy
14.5 vaccine	efficacy	of	something	that	is	free
15
immunization	as	a	social	norm	vs.	not	needed	/	harmful	(need	for	
vaccine,	necessary)
immunization	as	a	social	norm	vs.	not	needed	/	harmful	(need	for	
vaccine,	necessary)
16 vaccine	specific	issues	(general/other) vaccine	specific	issues	(general/other)
17 risk/benefit	(scientific	evidence)
17.1 use	of	evidence
17.2 trust	in	evidence
18 introduction	of	a	new	vaccine	or	new	formulation introduction	of	a	new	vaccine	or	new	formulation
19 mode	of	administration mode	of	administration
20 design	of	vaccination	program,	mode	of	delivery
20.1 absent	from	vax	site	(absent	from	school,	not	at	home	during	delivery)
20.2 procedural	issues	(multi-stage,	problems	with	vax	booklet/card
20.3 limited	open	hours/days
21 reliability	and/or	source	of	vaccine	supply
21.1 vaccine	not	available
22 vaccination	schedule vaccination	schedule
23 costs
23.1 financial	(cost	of	vaccine	itself)
23.2 time	(interruption	of	time	normally	spent	on	other	
activities/responsibilities)
23.3 administrative
23.4 access	(cost	of	transportation)
23.5 inability	to	access	to	due	to	ability,	or	illness	(of	recipient	or	caregiver)
24 role	of	healtcare	professionals
24.1 patient	communication
24.2 vaccination	expectations
24.3 organizational	culture
24.4 place	of	work
995 already	had	the	vaccine/vpd
996 general,	nonspecified	access	issues,	no	opportunity
997 unclear	relevance
998 reason	not	specified	(not	data? )
999 other	reason
Appendix	4:	Qualitative	codeframe
other other
vaccine	specific	
issues
risk/benefit	(scientific	evidence)
design	of	vaccination	program,	mode	of	delivery
reliability	and/or	source	of	vaccine	supply
costs
role	of	healtcare	professionals
contextual	
influences
communication	&	media	environment
religion/culture/gender/socioeconomic
politics/policies/mandates
individual/group	
influences
beliefs/attitudes	about	health	and	prevention
knowledge/awareness
health	system	and	providers-trust	and	personal	experience
risk/benefit	(perceived,	hueristic)
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Appendix 5: SAGE WG Determinants of Vaccine Hesitancy (definitions) 
SAGE Determinant Description 
contextual influences Influences arising due to historic, socio- cultural, environmental, health system/institutional, 
economic or political factors  
communication & media environment Media and social media can create a negative or positive vaccine sentiment and can provide a 
platform for lobbies and key opinion leaders to influence others; social media allows users to 
freely voice opinions and experiences and it can facilitate the organization of social networks 
for or against vaccines .  
influential leaders, gatekeepers and 
anti-/pro- vaccination lobbies 
Community leaders and influencers, including religious leaders in some settings, celebrities in 
others, can all have a significant influence on vaccine acceptance or hesitancy.  
historical influences Historic influences (such as the negative experience of the Trovan trial in Nigeria) can 
undermine public trust and influence vaccine acceptance, as it did for polio, especially when 
combined with pressures of influential leaders and media. A community’s experience isn’t 
necessarily limited to vaccination but may affect it.  
religion/culture/gender/socioeconomic A few examples of the interplay of religious/cultural influences include: Some religious leaders 
prohibit vaccines; Some cultures do not want men vaccinating children; Some cultures value 
boys over girls and fathers don’t allow children to be vaccinated), 
politics/policies/mandates Vaccine mandates can provoke vaccine hesitancy not necessarily because of safety or other 
concerns, but due to resistance to the notion of forced vaccination  
geographic barriers A population can have general confidence in a vaccine and health service, and be motivated to 
receive a vaccine but hesitate as the health center is too far away or access is difficult.  
pharmaceutical industry Industry may be distrusted and influence vaccine hesitancy when perceived as driven only by 
financial motives and not in public health interest; This can extend to distrust in government 
when perceived that they are also being pushed by industry and not transparent.   
individual/group influences Influences arising from personal perception of the vaccine or influences of the social/peer 
environment  
experience with past vaccination Past negative or positive experience with a particular vaccination can influence hesitancy or 
willingness to vaccinate. Knowledge of someone who suffered from a VPD due to non­ 
vaccination may enhance vaccine acceptance. Personal experience or knowledge of someone 
who experienced an AEFI can also influence hesitancy.  
beliefs/attitudes about health and 
prevention 
Vaccine hesitancy can result from 1) beliefs that vaccine preventable diseases (VPD) are 
needed to build immunity (and that vaccines destroy important natural immunity) or 2) beliefs 
that other behaviors (breastfeeding, traditional/alternativ e medicine or naturopathy) are as 
or more important than vaccination to maintain health and prevent VPDs.  
knowledge/awareness Decisions to vaccinate or not are influenced by a number of the factors addressed here, 
including level of knowledge and awareness. Vaccine acceptance or hesitancy can be affected 
by whether an individual or group has accurate knowledge, a lack of awareness due to no 
information, or misperceptions due to misinformation. Accurate knowledge alone is not 
enough to ensure vaccine acceptance, and misperceptions may cause hesitancy, but still result 
in vaccine acceptance.  
health system and providers-trust and 
personal experience 
Trust or distrust in government or authorities in general, can affect trust in vaccines and 
vaccination programmes delivered or mandated by the government. Past experiences that 
influence hesitancy can includes system procedures that were too long or complex, or 
personal interactions were difficult.  
risk/benefit (perceived, heuristic) Perceptions of risk as well as perceptions of lack of risk can affect vaccine acceptance. 
Complacency sets in when the perception of disease risk is low and little felt need for 
vaccination. E.g. Patient’s or caregiver’s perceptions of their own or their children’s risk of the 
natural disease or caregivers’ perceptions of how serious or life threatening the VPD is.  
immunization as a social norm vs. not 
needed / harmful 
Vaccine acceptance or hesitancy is influenced by peer group and social norms  
 
vaccine specific issues Directly related to vaccine or vaccination  
risk/benefit (scientific evidence) Scientific evidence of risk/benefit and history of safety issues can prompt individuals to 
hesitate, even when safety issues have been clarified and/or addressed.  e.g. suspension of 
rotavirus vaccine due to intussusception; Guillain­Barre syndrome following swine flu vaccine 
(1976) or narcolepsy (2011) following (A)H1N1 vaccination; milder, local adverse events can 
also provoke hesitancy.  
introduction of a new vaccine or new 
formulation 
Individuals may hesitate to accept a new vaccine when they feel it has not been used/tested 
for long enough or feel that the new vaccine is not needed, or do not see the direct impact of 
the vaccine (e.g. HPV vaccine preventing cervical cancer). Individuals may be more willing (i.e. 
not complacent) to accept a new vaccine if perception of the VPD risk is high.  
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mode of administration Mode of administration n can influence vaccine hesitancy for different reasons. E.g. oral or 
nasal administration ns are more convenient and may be accepted by those who find 
injections fearful or they do not have confidence in the health workers skills or devices used.  
design of vaccination program, mode 
of delivery 
Delivery mode can affect vaccine hesitancy in multiple ways. Some parents may not have 
confidence in a vaccinator coming house­to­ house; or a campaign approach driven by the 
government. Alternatively if a health centre is too far or the hours are inconvenient  
reliability and/or source of vaccine 
supply 
Individuals may hesitate if they do not have confidence in the system’s ability to provide 
vaccine(s) or might not have confidence in the source of the supply (e.g. if produced in a 
country/culture the individual is suspicious of) ; health workers may also be hesitant to 
administer a vaccine (especially a new one) if they do not have confidence that the supply will 
continue as it affects their clients trust in them. Caregivers may not have confidence that a 
needed vaccine and or health staff will be at the health facility if they go there. 
vaccination schedule Although there may be an appreciation for the importance of preventing individual vaccine 
preventable diseases, there may be reluctance to comply with the recommended schedule 
(e.g. multiple vaccines or age of vaccination).  Vaccination schedules have some flexibility that 
may allow for slight adjustment to meet individual needs and preferences. While this may 
alleviate hesitancy issues, accommodating individual demands are not feasible at a population 
level. 
costs An individual may have confidence in a vaccine’s safety and the system that delivers it, be 
motivated to vaccinate, but not be able to afford the vaccine or the costs associated with 
getting themselves and their child(ren) to the immunization point. Alternatively, the value of 
the vaccine might be diminished if provided for free.  
role of healthcare professionals Health care professionals (HCP)are important role models for their patients; if HCPs hesitate 
for any reason (e.g. due to lack of confidence in a vaccine’s safety or need) it can influence 
their clients’ willingness to vaccinate  
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INTRODUCTION
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regulatory and governmental agencies, charities, and health and industry professionals.
Types of paper
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infectious diseasesVeterinary VaccinesImmunology and Animal ModelsVectors, Adjuvants and Drug
DeliveryProduction, manufacturing and SafetyRegulatory, Societal and Legislation Aspects
For more specifics please go to ARTICLE TYPE - GUIDELINES
Vaccine also welcomes thoughtful opinion pieces and similar commentary on topics of interest to
the readership of the journal. Authors proposing such work should contact Elena Kostova, Managing
Editor (e.kostova@elsevier.com), in advance of its preparation to describe the general subject of the
article in order for a formal solicitation to be made. Authors who wish to submit a review article
should also seek approval of topic before submission. Please send enquiry to the Managing Editor.
However, the resulting submission is still subject to standard peer review, and the solicitation does
not guarantee acceptance for publication.
Contact details for submission
Papers should be submitted using the Vaccine online submission system, http://ees.elsevier.com/jvac
10 essentials to ensure fast handling
Manuscript is in accordance with ARTICLE TYPE - GUIDELINES Manuscript-text is saved as a Word-
file, line-numbers are added and text is double spaced Clinical trial registry is mentioned at the end
of the abstract if applicable Conflict of interest statement is included at the end of the manuscript
Figures and tables are prepared as separate files and are clearly labeled Cover letter is prepared,
introducing your article and explaining the novelty of the research Keywords are prepared Contact
details of 4-6 suggested reviewers (Name, affiliation and email address) are prepared Highlights are
prepared (a birds' eye view of your article in 3-5 points, 85 characters each) The work presented in
the article has been carried out in an ethical way
For any further information please consult this Guide For Authors or visit our customer support site
at http://support.elsevier.com
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for
review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
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• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
• Relevant declarations of interest have been made
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
BEFORE YOU BEGIN
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Human and animal rights
If the work involves the use of human subjects, the author should ensure that the work described has
been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to
Biomedical journals. Authors should include a statement in the manuscript that informed consent
was obtained for experimentation with human subjects. The privacy rights of human subjects must
always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in
accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU
Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care
and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should
clearly indicate in the manuscript that such guidelines have been followed.
Policy and ethics (additional information)
Informed consent
Investigations on human subjects must include a statement indicating that informed consent was
obtained after the nature and possible consequences of the studies had been fully explained.
Animal welfare
Authors using experimental animals must state that their care was in accordance with institutional
guidelines. For animals subjected to invasive procedures, the anesthetic, analgesic and tranquilizing
agents used, as well as the amounts and frequency of administration, must be stated.
Availability of Materials
Publication of an article in Vaccine is taken to imply that the authors are prepared to freely distribute
materials used in the published experiments (e.g. antibodies, cell lines) to academic researchers for
their own use.
Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations
that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include
employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/
registrations, and grants or other funding. If there are no conflicts of interest then please state this:
'Conflicts of interest: none'. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except
in the form of an abstract or as part of a published lecture or academic thesis or as an electronic
preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more
information), that it is not under consideration for publication elsewhere, that its publication is
approved by all authors and tacitly or explicitly by the responsible authorities where the work was
carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or
in any other language, including electronically without the written consent of the copyright-holder. To
verify originality, your article may be checked by the originality detection service CrossCheck.
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Contributors
Each author is required to declare his or her individual contribution to the article: all authors must have
materially participated in the research and/or article preparation, so roles for all authors should be
described. The statement that all authors have approved the final article should be true and included
in the disclosure.
Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and
design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the
article or revising it critically for important intellectual content, (3) final approval of the version to
be submitted.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their
manuscript and provide the definitive list of authors at the time of the original submission. Any
addition, deletion or rearrangement of author names in the authorship list should be made only
before the manuscript has been accepted and only if approved by the journal Editor. To request such
a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.
Reporting clinical trials
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript
submission, authors must provide the CONSORT checklist accompanied by a flow diagram that
illustrates the progress of patients through the trial, including recruitment, enrollment, randomization,
withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT
checklist and template flow diagram are available online.
All scientific communications describing immunogenicity, effectiveness, or efficacy of a human or
veterinary vaccine must include the following details: Vaccine characteristics: Vaccine lot number,
manufacturer, dosing interval and number of doses, vaccine route of administration, if an injection
- the anatomic site of injection, technique for vaccine administration (if by injection, specify
needle length), concomitant vaccines administered, cold chain or storage effects if relevant, and a
specification of what vaccine antigens and adjuvants were administered. Subject characteristics: Age,
race, ethnicity, body mass index or body weight, smoking status, gender, medical/immunologic status,
and concomitant drug use.
Statistical and analytical reporting
Author guidelines for statistical and analytical reporting:
AUTHOR GUIDELINES
Statistical and analytical guidelines checklist:
STATISTICAL AND ANALYTICAL GUIDELINES CHECKLIST
Registration of clinical trials
Registration in a public trials registry is a condition for publication of clinical trials in this journal
in accordance with International Committee of Medical Journal Editors recommendations. Trials
must register at or before the onset of patient enrolment. The clinical trial registration number
should be included at the end of the abstract of the article. A clinical trial is defined as any
research study that prospectively assigns human participants or groups of humans to one or more
health-related interventions to evaluate the effects of health outcomes. Health-related interventions
include any intervention used to modify a biomedical or health-related outcome (for example drugs,
surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care
changes). Health outcomes include any biomedical or health-related measures obtained in patients or
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participants, including pharmacokinetic measures and adverse events. Purely observational studies
(those in which the assignment of the medical intervention is not at the discretion of the investigator)
will not require registration.
Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is
more suitable in one of our other participating journals, then you may be asked to consider transferring
the article to one of those. If you agree, your article will be transferred automatically on your behalf
with no need to reformat. Please note that your article will be reviewed again by the new journal.
More information.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version
of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for
use by authors in these cases.
For open access articles: Upon acceptance of an article, authors will be asked to complete an
'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles
is determined by the author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More
information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply
with their funder's open access policies. Some funding bodies will reimburse the author for the Open
Access Publication Fee. Details of existing agreements are available online.
Open access
This journal offers authors a choice in publishing their research:
Open access
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder
or institution.
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our universal access programs.
• No open access publication fee payable by authors.
Regardless of how you choose to publish your article, the journal will apply the same peer review
criteria and acceptance standards.
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For open access articles, permitted third party (re)use is defined by the following Creative Commons
user licenses:
Creative Commons Attribution (CC BY)
Lets others distribute and copy the article, create extracts, abstracts, and other revised versions,
adaptations or derivative works of or from an article (such as a translation), include in a collective
work (such as an anthology), text or data mine the article, even for commercial purposes, as long
as they credit the author(s), do not represent the author as endorsing their adaptation of the article,
and do not modify the article in such a way as to damage the author's honor or reputation.
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or
modify the article.
The open access publication fee for this journal is USD 2300, excluding taxes. Learn more about
Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of
green open access options available. We recommend authors see our green open access page for
further information. Authors can also self-archive their manuscripts immediately and enable public
access from their institution's repository after an embargo period. This is the version that has been
accepted for publication and which typically includes author-incorporated changes suggested during
submission, peer review and in editor-author communications. Embargo period: For subscription
articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers
before an article becomes freely available to the public. This is the embargo period and it begins from
the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who feel their English language manuscript may require editing to eliminate possible
grammatical or spelling errors and to conform to correct scientific English may wish to use the English
Language Editing service available from Elsevier's WebShop.
Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which
should be documented in the paper. Appropriate consents, permissions and releases must be obtained
where an author wishes to include case details or other personal information or images of patients
and any other individuals in an Elsevier publication. Written consents must be retained by the author
and copies of the consents or evidence that such consents have been obtained must be provided to
Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or
Personal Information of Patients or other Individuals. Unless you have written permission from the
patient (or, where applicable, the next of kin), the personal details of any patient included in any
part of the article and in any supplementary materials (including all illustrations and videos) must
be removed before submission.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/jvac
Referees
Suggestions for potential reviewers
Authors are invited to provide the names, and e-mail addresses of up to five potential reviewers.
It would not be appropriate to nominate individuals that have had any input into the manuscripts
submitted or any recent collaboration with the authors. The Editors may or may not take these
suggestions into account during the reviewing process.
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Review process
All contributions are read by two or more referees to ensure both accuracy and relevance, and
revisions to the script may thus be required. On acceptance, contributions are subject to editorial
amendment to suit house style. When a manuscript is returned for revision prior to final acceptance,
the revised version must be submitted as soon as possible after the author's receipt of the referee's
reports. Revised manuscripts returned after four months will be considered as new submissions
subject to full re-review.
PREPARATION
Use of wordprocessing software
It is important that the file be saved in the native format of the wordprocessor used. The text should
be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes
will be removed and replaced on processing the article. In particular, do not use the wordprocessor's
options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts
(see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Note that
source files of figures, tables and text graphics will be required whether or not you embed your figures
in the text. Source files must have "consecutive" line numbering added by authors (this must include
tables, captions, references).See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your wordprocessor.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced, with details of supplier and catalogue
number when appropriate. Methods already published should be indicated by a reference: only
relevant modifications should be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that the e-mail address is given and that contact
details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
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Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images and in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights
are optional and should be submitted in a separate editable file in the online submission system.
Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters,
including spaces, per bullet point). You can view example Highlights on our information site.
Stereochemistry abstract
For each important chiral compound you are requested to supply a stereochemistry abstract detailing
structure, name, formula and all available stereochemical information for eventual incorporation into
a database. An abstract for only one enantiomer per compound is required.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding
general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with
abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will
be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
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Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If
other units are mentioned, please give their equivalent in SI.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in
line with normal text where possible and use the solidus (/) instead of a horizontal line for small
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often
more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate
the position of footnotes in the text and list the footnotes themselves separately at the end of the
article. Do not include footnotes in the Reference list.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
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Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
A DOI can be used to cite and link to electronic articles where an article is in-press and full citation
details are not yet known, but the article is available online. A DOI is guaranteed never to change,
so you can use it as a permanent link to any electronic article. An example of a citation using DOI
for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M.
(2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal
of Geophysical Research, http://dx.doi.org/10.1029/2001JB000884i. Please note the format of such
citations should be in the same style as all other references in the paper.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/vaccine
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
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Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2010;163:51–9.
Reference to a book:
[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.
Reference to a website:
[4] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13.03.03].
Reference to a dataset:
[dataset] [5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/
xwj98nb39r.1.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for
Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples
of Formatted References).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
Supplementary material captions
Each supplementary material file should have a short caption which will be placed at the bottom of
the article, where it can assist the reader and also be used by search engines.
Data linking
If you have made your research data available in a data repository, you can link your article directly to
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with
relevant repositories, giving readers access to underlying data that give them a better understanding
of the research described.
There are different ways to link your datasets to your article. When available, you can directly link
your dataset to your article by providing the relevant information in the submission system. For more
information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published
article on ScienceDirect.
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In addition, you can link to relevant data or entities through identifiers within the text of your
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053;
PDB: 1XFN).
ARTICLE ENRICHMENTS
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
Google Maps and KML files
KML (Keyhole Markup Language) files (optional): You can enrich your online articles by providing
KML or KMZ files which will be visualized using Google maps. The KML or KMZ files can be uploaded
in our online submission system. KML is an XML schema for expressing geographic annotation and
visualization within Internet-based Earth browsers. Elsevier will generate Google Maps from the
submitted KML files and include these in the article when published online. Submitted KML files will
also be available for downloading from your online article on ScienceDirect. More information.
Interactive plots
This journal enables you to show an Interactive Plot with your article by simply submitting a data
file. Full instructions.
AFTER ACCEPTANCE
News and embargoes
If you think your article would be interesting for a wider audience, we would be happy to hear from
you. Please contact the Journal Manager, John Bailey (jd.bailey@elsevier.com) and we'll send you an
information form to complete. You must inform the Journal Manager if you are planning publicity for
your article through your institution or funding body. Any publicity materials must be approved by
Elsevier before release, and must not be distributed before the article has been published.
Uncorrected proofs of articles are published online on ScienceDirect as soon as they are available. As
such, information about embargoes is not available. Authors can track the status of their article via
the Track Your Accepted Article service. Uncorrected articles are normally available online within
two working days of you receiving the email to download the proofs.
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
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time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
© Copyright 2014 Elsevier | http://www.elsevier.com
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